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Before I got involved in research, a friend of a friend of mine had told me that taking a PhD is 
a piece of cake: “You only need to write three articles and that’s it.” Little was I aware of the 
extensive work with planning, organizing, coordinating, reporting, funding, data collection, 
registrations, investigating, writing and analyzing, being interdependent, disputing with 
people that had different agendas, etc. The following project was planned in 2008, and the 
researchers started recruiting patients from a small rural hospital in Mosjøen, Northern 
Norway in 2009. Due to different complications, the pilot study was stopped and put on ice 
for a while. In 2012 it was reorganized into the project that I have worked on. I started to 
work on it in parallel with my clinical work as a neurologist at the Department of Neurology 
at Tromsø University Hospital. From September 2014 I got a grant from Helse Nord RHF, but 
kept on working my shifts at the Department of Neurology.   
 
At times, unforeseen events and major obstacles appeared. Despite the difficulties we had 
to overcome, I am very grateful to have been given the opportunity to work together with so 
many people. I feel honored and privileged to be a part of this project.   
First, I want to thank the 402 headache patients who participated in the trial. Your 
willingness to be consulted in a nontraditional manner and answering questionnaires made 
this work possible. Thank you very much! 
 
I would like to thank Svein Ivar Bekkelund, of whom I am indebted to for being the great 
supervisor who was in tune with my personality. You introduced me to the world of science, 
gave me the opportunity to learn, and taught me the importance of teamwork, 
interdependency, and not to forget to get the most out of the available resources.  
Special thanks goes to my co-supervisor Karl Bjørnar Alstadhaug. You have been great. Even 
when you were short of time, you always helped. I am especially grateful for your support, 
willingness and advice during my main supervisor’s absence. 
 
Claus Albretsen, thank you for arranging a hybrid model that made it possible to combine 
the research with clinical work. My colleagues at the Department of Neurology and 
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Neurophysiology, I would like to convey my special appreciation for your support and 
flexibility in a busy, but pleasurable work atmosphere.  
My warm thanks goes to Jorun Willumsen and Anna-Kirsti Kvitnes who skillfully coordinated 
the project, and joined me to test the different functions of the equipment (Figure 1). I do 
want to express my gratitude to Irene Lund and the National Neuromuscular Centre (NMK) 
for providing us with such excellent study coordinators. The secretaries at the Department of 
Neurology also helped coordinating patients. Lilly Ann Klaussen was excellent in managing 
administrative tasks. Marlen Lauritsen and Nora Bekkelund, your data collection and plotting 
have been very helpful.    
 
 
Figure 1 Conversation between me and the study coordinator to test the telemedicine 
equipment. A computer screen with the electronic patient record is seen on the right. 
 
Karin Flatekval Eines, Torill Erdahl, Marianne Røst, and Grethe Berg Johnsen from the 




Staff at the research department made valuable contributions with randomization and study 
advice. I especially want to mention Bjørn Straume, who gave valuable statistical advice. At 
Tromsø University Hospital, I am in debt to economist Thomas Krogh, who contributed with 
data collection and cost analyses in article 1. Thanks to my fellow PhD students and staff at 
EPINOR, in which it was a pleasure to be a part of.  
I am also indebted to the following organizations:  
- The Northern Norway Regional Health Authority (Helse Nord RHF) that funded the 
study. 
- The University of Tromsø (UIT) that gave me the opportunity to become a PhD 
student and finally dispute. 
 
To my wife Margrethe, and our children Jakob and Jahn for enriching these days.  
 
The present PhD project began as an innocent commitment, and ended with a separation 
that gave me new paradigms, and hopefully will open new doors. To all who were involved, I 
give my sincere thanks and appreciation, for giving me inspiration and challenges as well as 
experiences with enrichments and friendships I would not have otherwise known.  
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CHEERS  Consolidated Health Economic Evaluation Reporting Standards  
CONSORT CONsolidated Standards Of Reporting Trials 
CT  Computer Tomography 
DIPS  The Distributed Information and Patient System for hospitals (DIPS ASA, Bodø, 
Norway) 
EPR  Electronic Patient Record 
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HIT-6   Headache Impact Test-6  
ICER   Incremental Cost Effectiveness Ratio  
ICHD   International Classification of Headache Disorders 
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IHS   International Headache Society 
IT  Information Technology 
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MRI  Magnetic Resonance imaging 
PC  Personal Computer  
RCT  Randomized Controlled Trial 
REC  Norwegian National Committee for Medical and Health Research Ethics 
SPSS  Statistical Package for Social Science  
SUNCT  Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival 
injection and Tearing  
SUNA   Short-lasting Unilateral Neuralgiform headache attacks with cranial 
Autonomic symptoms  
TAC  Trigeminal Autonomic Cephalalgia 
VAS   Visual Analogue pain Scale 







Hodepine er en av de vanligste plager hos mennesket, og er også den hyppigste årsaken til at 
pasienter oppsøker helsevesenet. På grunn av det store geografiske dekningsområdet for to 
nevrologiske avdelinger i Nord-Norge, mangler mange hodepinepasienter tilgjengelighet til 
god spesialisthelsetjeneste. Mangel på hodepinespesialister og tungvinn tilgang til omsorg 
kan gi grobunn for feildiagnostisering, ikke optimal behandling og vansker med oppfølging av 
hodepinepasienter. 
 
Vi ønsker å kompensere for disse uheldige forholdene, og laget en randomisert kontrollert 
ikke-underlegenhetsstudie i et forsøk på å vise om telemedisin og tradisjonelle 
hodepinekonsultasjoner på kontoret hos nevrolog gir ulike resultater. For å utføre dette, 
sammenlignet vi telemedisin med tradisjonelle konsultasjoner i pasienttilfredshet, 
behandling, sikkerhet og egnethet. I tillegg vurderte vi aksepten av telemedisin fra 
hodepinepasienten, og estimerte kostnadsbesparelser. 
 
Resultatene viste at de fleste hodepinepasienter aksepterer telemedisin, og er fornøyd med 
konsultasjonsmetoden. Så og si alle endepunktene i studien viste at hodepinekonsultasjoner 
via telemedisin ikke er underlegen tradisjonelle nevrologiske konsultasjoner. Vi anser derfor 
telemedisin som et godt alternativ for de fleste pasienter med ikke akutt hodepine. Denne 
studien vil være et fundament til å fremme videre forskning på ehelsetjenester, og for 













Headaches are one of the most common complaints among humans as well as the most 
frequent reason for patients seeking health-care. Due to the huge geographical area of 
coverage for the two Departments of Neurology in Northern Norway, headache patients 
have variable accessibility and availability to proper specialist care. Few headache specialists 
and poor access to care may lead to misdiagnosis, suboptimal treatment and inconvenience 
with follow-up plans for headache patients.  
 
We want to compensate for these unfortunate conditions, and designed a non-inferiority 
randomized controlled trial in an attempt to demonstrate whether there are differences in 
outcome of neurologic consultations depending on assessment method; telemedicine versus 
traditional in-person headache visits. To accomplish this, we investigated endpoints of 
different aspects, and compared telemedicine to traditional visits in patient satisfaction, 
treatment efficacy, safety and feasibility. Additionally, we assessed headache patients’ 
acceptability of telemedicine, and evaluated the cost savings.  
 
The results showed that most headache patients accept telemedicine, and are satisfied with 
the consultation type. Virtually all endpoints in the trial indicated that specialist headache 
visits via telemedicine is non-inferior to traditional in-patient visits. We thus consider 
telemedicine as a good alternative for most patients with nonacute headache referred to a 
secondary neurology department. This trial will serve as a base for further research on 
ehealth services, and for the establishment of telemedicine consultations for headache 
patients in clinical practice.    












 This thesis is based on the following articles:  
I. Acceptability, Feasibility, and Cost of Telemedicine for Nonacute Headaches: A 
Randomized Study Comparing Video and Traditional Consultations.  
Müller KI, Alstadhaug KB, Bekkelund SI.  
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1. INTRODUCTION  
Data acquired from several epidemiological studies show that within one year, the global 
prevalence of an active headache was 47%; migraine 10%, tension type headache 38% and 
chronic daily headache 3% [1]. During a lifetime, headaches will be experienced by more 
than 9 out of 10 individuals [2]. Tension-type headache and migraine are respectively the 
second and fourth most prevalent disorders in the world [3]. Together with Medication 
Overuse Headache (MOH) they are the first, second and third most prevalent neurologic 
disorders [3, 4]. Since these nonacute headaches are extremely common, they represent the 
most frequent neurologic reason for patients visiting primary care doctors as well as 
neurologists [5-8]. Migraineurs are those who most frequently seek primary, secondary and 
tertiary health-care [6, 8]. During our trial, that lasted 2.5 years, 557 out of 6193 (9%) 
patients were referred to our neurologic department in Tromsø city due to nonacute 
headache. A total of 6040 consultations were made, including the 402 (6.7%) that 
participated in our trial.  
 
In the Global Burden of Disease study, migraine was the seventh leading cause of years lived 
with disability, while medication overuse headache was the 20tieth [3, 9]. It is reason to 
believe that the influence of headaches on daily life is high in the population of northern 
Norway as well [10].  
 
Due to the high prevalence and burden of these headaches, general practitioners and 
neurologists must have proper knowledge to be able to adequately handle nonacute 
headache disorders. Unfortunately, physicians often find these conditions challenging to 
diagnose and treat [11-14]. Cumbersome access to care and lack of availability of 
neurologists and headache specialists add to the known under-diagnoses, misdiagnoses and 
suboptimal treatment of headache sufferers, and leads to patients being less satisfied with 
their health care [15].    
 
The cost of headaches is tremendous, and it illustrates the high burden in monetary units. A 
study in 27 countries of the European Union (the United Kingdom included), from November 
2008 until August 2009, estimated the total annual direct and indirect cost of adult 
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headache patients to €173000 million [16]. In 2010, another study estimated a total 
headache cost of €43514 million in the EU countries, the UK, Iceland, Norway and 
Switzerland [17]. Migraine, which accounts for an annual cost of €111000 million [16], is the 
third most costly neurologic disorder, only exceeded by dementia and stroke [8]. 
 
Northern Norway has a widespread geography with many sparsely populated areas (Figure 
2). The poor weather conditions, and many valleys and fjords make travelling burdensome 
and expensive. During the study, the estimated annual travel cost, based on the cheapest 
means of public transport from the Norwegian Patient Travel Agency, of patients to our 
neurologic outpatient department was €381320 (11486 patients*83 median/2,5).  
 
The main motivations for this trial were the high frequency and burden of headaches in the 
society, the poor access and availability to headache specialist competence, and the 
expensive and time consuming travel conditions in our region. Although telemedicine has 
the potential to be interdependent of location, information and communication 
technologies are too often implemented without proper analysis of the health care that is 
delivered [18-20]. The intention of this trial is not to wire all of our neurologic headache 
consultations, but to enable a change to meet headache patients and their needs. We have 
investigated different perspectives of telemedicine visits for nonacute headaches before 
planning to adopt it into clinical practice. This thesis aims at answering whether telemedicine 






Figure 2 The Department of Neurology at the University Hospital of North Norway is located 
at 69◦N in the city of Tromsø (red dot). Patients were recruited from almost all of Northern 
Norway. Inserted in the figure is the archipelago of Svalbard. Norway Statistics 31.12.2014. 




2.1 Headache diagnosis and classification 
Headaches can be caused by a wide spectrum of disorders. The diversity of causes ranges 
from trivial to more complex conditions, from short-lived remitting to unremitting, and from 
benign to life threatening disorders. Due to the high prevalence of headaches, and the 
different underlying causes, a classification is required to enable valid diagnosis for research 
purposes, but is also a valuable tool to differentiate headache disorders in clinical practice.  
 
The International Headache Society (IHS) has developed such a framework in the 
International Classification of Headache Disorders (ICHD). Since the first paper based edition 
of ICHD in 1988, the characteristics of these headaches have gradually evolved, and are 
based on both empirical evidence and expert consensus [21]. Today, the classification 
system is in use in both clinical practice and research. The ICHD classification is considered 
indispensable, and every headache patient entered into a research project, be it a study of 
telemedicine, a drug trial or a study of pathophysiology or biochemistry, must fulfill a set of 
diagnostic criteria [21]. The latest version of the headache classification is the ICHD-3, which 
was published in 2013 [21]. Patients in our study were diagnosed according to the second 
version (ICHD-2) [22].  
 
According to the ICHD, headaches can be divided into two main categories; primary and 
secondary headaches [21].  
 
2.1.1 Primary headaches 
To avoid misdiagnosis, mistreatment and overlooking secondary causes, every primary 
headache is considered a diagnosis of exclusion [21, 23, 24]. This is reflected in a standard 
ICHD phrase, i.e. it should be “Not better accounted for by another ICHD- 3 diagnosis”. When 
no underlying cause is found, the headache is categorized as primary [21].  
 
There are 60 different primary headache diagnoses when subgroups of migraines and 
tension-type headaches are taken into account [21]. Only the main groups are mentioned 





Figure 3 Nonacute headaches referred to our Department of Neurology [25]. 
 
Migraine is the most common headache syndrome seen by doctors [6, 8], and it affects 10% 
of the worldwide population [1]. In adults, the female:male ratio is 3:1 [2, 26, 27], and the 1 
year prevalence is approximately 15-18% in women and 6 % in men [2, 26, 28]. There are 
five subtypes of migraine. Migraine without aura and migraine with aura constitute the vast 
majority. The ICHD-3 criteria for migraine without aura and chronic migraine are 
summarized in Table 1.  
 
Aura, which occurs in 15-30% of all migraineurs, is a transient focal neurologic omen strongly 
associated to migraine [29]. The most frequent aura is a visual disturbance prior to the 
headache that is experienced by more than nine of ten patients [21, 30]. Next in frequency 
are sensory phenomena in 30-50 %, and speech disturbances in 20-30% [21, 30, 31]. The 
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mentioned aura types most often follow in a temporal order, spreading gradually over ≥ 5 
minutes and lasting 5-60 minutes [21]. Usually the aura precedes a migraine headache, but 
not infrequently aura is followed by non-migraineous headache or no headache at all [21].  
 
Table 1 Diagnostic criteria for migraine without aura and chronic migraine.                                                                                        
                        
ICHD-3 diagnostic criteria for 1.1 migraine without aura and 1.3 chronic migraine                                                                                
              
A. ≥ five attacks fulfilling B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
C. Headache has at least two of the following four characteristics: 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe pain intensity 
4. Aggravation by or causing avoidance of routine physical activity  
D. During headache at least one of the following: 
1. Nausea and/or vomiting 
2. Photophobia and phonophobia 
E. Not better accounted for by another ICHD-3 diagnosis.                                                                                 
              
Chronic migraine is diagnosed when headache occurs ≥ 15 days per month for more than 3 
months, where ≥ 8 of days have the features of a migraine headache. Adapted from ICHD-3                                                                                                                                                 
                                                         
Tension type headache is not as disabling as migraine, but has great influence on 
socioeconomic and health care resources due to its high prevalence [9]. The headache lasts 
from 30 minutes to 7 days, is mild to moderate, and usually, but not mandatory it is located 
bilaterally [21]. It is a featureless headache with no more than one of photo- or 
phonophobia, but mild nausea is accepted in the chronic form [21]. Based on the attack 
frequency, it is divided into infrequent, frequent and chronic subtypes with or without 
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pericranial tenderness [21]. The headache of the chronic tension type should have occurred 
for ≥ 15 days per month for ≥ 3 months [21].  
 
Trigeminal Autonomic Cephalalgias (TACs) constitute a group of primary headaches 
characterized by unilateral pain accompanied by cranial autonomic symptoms [21]. The 
following conditions belong to this group: Episodic and chronic cluster headache, episodic 
and chronic paroxysmal hemicrania, episodic and chronic Short-lasting Unilateral 
Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT), episodic 
and chronic Short-lasting Unilateral Neuralgiform headache attacks with cranial Autonomic 
symptoms (SUNA) and hemicrania continua [21]. Of these, the latter (hemicrania continua) 
was added to the TACs in the third edition of ICHD [21, 22]. The other headache syndromes 
in the group are short-lasting. Both the paroxysmal hemicranias and hemicrania continua are 
considered as Indomethacin-responsive headaches, i.e. they should respond absolutely to 
Indomethacin [21, 32].  
 
A less common Indomethacin-responsive syndrome is the primary stabbing headache [32]. 
The condition is characterized by short stabbing pain (usually up to three seconds) from one 
to many stabs a day, and without cranial autonomic symptoms [21, 32]. Although considered 
Indomethacin-responsive, approximately 1/3 of these headaches do not respond to 
Indomethacin [33].      
 
Another headache syndrome is the new daily persistent headache. This is a continuous 
headache without remission, and often with characteristics of migraine and/or tension type 
headache [21]. However, the pathognomonic feature is that the headache has a distinct 
onset that is clearly remembered by the patient, without good response to preventive 
headache treatment [21, 34]. It may start out of the blue, but often appear in the wake of an 
infection or another stressful event [34].  
Table 2 and 3 provide typical clinical characteristics and common treatment options for the 






Table 2 Typical clinical characteristics of some primary headaches [21, 35] 
*Conjunctival injection/lacrimation, nasal congestion/rhinorrhea, eyelid oedema, forehead 





Headache  Duration Other features Intensity Localisation 










Episodic:                   
30 min. - 1 week 
Chronic:                       
≥ 15 days for ≥ 3 
months 
 
No more than one of 
photo- or 
phonophobia. 
Mild nausea is 












2-30 minutes Cranial autonomic 
symptoms* 




Chronic Cranial autonomic 
symptoms*  




≤ 3 seconds (80% of 
stabs) 





Chronic Photo-/ phonophobia 
or nausea 





Table 3 Documented pharmacological treatments of some primary headaches in the trial 
listed with reasonable doses [34-40]  
*Metoclopramid = Level B, Zolmitriptan = Level A/B. Except for primary stabbing headache 
and new daily persistent headache, the remaining medications are categorized as evidence 
level A. 
 
Headache  Abortive treatment  Preventive treatment  
Migraine Aspirin (1000 mg) 
Paracetamol (1000 mg) 
Diclofenac (50 -100 mg) 
Ibuprofen (200 -800 mg) 
Naproxen (500 -1000 mg) 
Metoclopramide* (20 mg)  
Triptans 
Propranolol (40- 160 mg daily) 
Metoprolol (50-200 mg daily)  
Flunarizine (5-10 mg  daily) 
Topiramate (25-200 mg daily) 
Sodium valproic acid (500-1800 mg daily) 




Aspirin (500-1000 mg) 
Ibuprofen (200 -800 mg) 
Amitriptyline (10-75 mg nocte) 
Cluster headache 100% oxygen (15 l/ min)    
Sumatriptan (6 mg s.c. or 20 
mg nasal)  
Zolmitriptan* (10 mg nasal) 
Verapamil (240-960 mg daily) 
Steroids (e.g. prednisolon 60 mg daily for 5 




- Indomethacin (up to 225 mg daily) 
Hemicrania 
Continua 
- Indomethacin (up to 225 mg daily) 
Primary stabbing 
headache 




- According to phenotype 
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2.1.2 Secondary headaches 
When the underlying cause is identified, or if a presumed causal factor with close temporal 
relationship to the headache is present, the headache is categorized as secondary [21]. More 
than 90% of all headaches are considered primary [41], but the share of secondary 
headaches tends to be higher in the elderly [42]. Most of these, however, are attributed to 
headache caused by trauma/injury to the head and/or neck, and headache attributed to 
intake or withdrawal of substances [42]. To achieve correct treatment, it is important to 
differentiate primary headaches from secondary headaches. 
 
The far most common secondary headache that seeks medical attention is MOH. The 
prevalence of MOH varies between 0.5%-7% in population studies [43], and the headache 
condition is found in more than 30% of patients in headache clinics [44]. Overuse of pain 
relieving drugs (Paracetamol, NSAIDS, opioids, triptans, barbiturates, etc.) may give a 
paradoxical effect that increases headache frequency and causes chronic headache (MOH) 
[4, 44]. MOH pathophysiology is not well understood [45], but a preexisting headache is 
required [44]. In practice, migraine or tension type headache is the underlying primary 
headache condition. Table 4 presents the ICHD-3 criteria for medication overuse headache 
[21]. The recommended treatment is patient information and education, abrupt or tapering 
withdrawal of the headache overused medication(s), and eventually prophylaxis [44-47]. A 
meta-analysis published in 2016 concluded that there is little evidence regarding effective 
preventive medications for MOH, and that the withdrawal of the overused medications 
therefore remains the best documented advice [48]. Additionally, another recent published 
study reported effective treatment by a brief intervention method administered by general 











                                                                                  
Table 4 ICHD-3 diagnostic criteria for 8.2 Medication Overuse Headache                             
                                            
A. Headache occurring on ≥ 15 days per month.  
B. Regular overuse for > 3 months of one or more drugs that can be taken for acute 
and/or symptomatic treatment of headache (1-7). 
C. Not better accounted for by another ICHD-3 diagnosis. 
                                                              
1. Regular intake of ergotamine on ≥ 10 days per month for > 3 months. 
2. Regular intake of one or more triptans on ≥ 10 days per month for > 3 months. 
3. Regular intake of simple analgesic (Paracetamol and/or NSAIDS) on ≥ 15 days per 
month for > 3 months. 
4. Regular intake of one or more opioids1 on ≥ 10 days per month for > 3 months. 
5. Regular intake of one or more combination-analgesic medications on ≥ 10 
days/month for > 3 months. 
6. Regular intake of any combination of ergotamine, triptans, simple analgesics, NSAIDs 
and/or opioids on a total of ≥ 10 days per month for > 3 months without overuse of 
any single drug alone. 
7. Regular overuse, on ≥ 10 days per month for > 3 months, of one or more medications 
other than those described above, taken for acute or symptomatic treatment of 
headache. 










Malignant secondary causes of nonacute headaches are rare [41, 42], and the frequency of 
secondary intracranial pathologies is less than 2% in most studies [49-57]. During a headache 
consultation, physicians should aim at identifying red flags. These flags are alarming signs 
that indicate a secondary headache cause, and warrant further investigation. Worrisome red 
flags are listed in table 5.  
 
 






- Focal neurologic signs (e.g. papilledema, cranial nerve palsy, paresis, hypoesthesia) 
- Neurologic symptoms (e.g. altered mental status, syncope, seizures, focal signs) 
- Sudden onset of headache (e.g. subarachnoid hemorrhage) 
- New onset headache > 50 years (e.g. tumor, giant cell arteritis) 
- Atypical headache (Headache not clearly belonging to any category of ICHD-3) 
- Headache progression, change in intensity, frequency or feature (e.g. tumor, 
hemorrhage and vasculitis) 
- Systemic symptoms (fever, stiff neck, rash, weight loss, chills, night sweats) 
- Risk factors (e.g. cancer, HIV) 
- Dynamic in nature (triggered/worsened by cough, other Valsalva maneuvers, 
exertion and sexual activity) 
20 
 
2.2 Headache consultation methods 
The gold standard for a specialist headache visit is an in-person face-to-face consultation 
between the specialist doctor and the patient. The in-person visits have gradually changed as 
technology has evolved. When the Personal Computer (PC), the Mac, and the Linux entered 
the mainstream in the late 80ties, it started a transformation to a more digitalized health-
care [61, 62]. In this century, health-care has gradually gone from paper based medical 
records to electronic patient records in Europe and the US [61, 63-65]. Although, this shift 
gave doctors better access to the patients’ medical records, it also changed the traditional 
in-person consultations, and doctors often seemed to be more focus oriented on the 
computer screen than on the patient [61]. Today, giving medical help by ordinary letter mail 
has also changed, and is often replaced by e-mail, but privacy rules and regulations prevents 
health care personnel to use unencrypted email.         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Another consultation type that has existed for over a century is the telephone consultation. 
The first telephone consultation was reported in Lancet in 1897, 21 years after Alexander 
Graham Bell invented the telephone [66]. As the telephone access increased, so did its use in 
health care. Today it is used to handle a wide variety of chronic and acute conditions, but 
absence of nonverbal communication is of course a major limitation [67]. In specialist 
headache care, telephone consultations have been recognized as an extensive part of daily 
work [68]. However, its feasibility as a headache behavioral modifying and motivational tool 
has been assessed with diverging results [69-71]. It is recommended that telephone 
consultations ought to follow a certain pattern, and that they are made by health care 
personnel who are trained in such delivery [67].  
 
When the Internet evolved during the 90ties, new consultation possibilities accompanied 
[62]. By the increased broadband access, use of telemedicine consultations through fixed 
and mobile devices such as PC, laptops, tablets, smartphones and even smartwatches 
became evident. Regardless of the consultation method, well developed communication and 




2.2.1 Traditional in-person headache consultations 
This consultation form has an in-person relationship between the patient and the 
neurologist. For decades, the cornerstone of the traditional headache consultation has been 
a thorough headache interview combined with a neurologic examination. In addition, 
present and past medical history, family history, social and psychological factors should be 
known. The interview is considered as the most important part of the traditional headache 
consultation [41].  
 
To stimulate the patient to talk freely, it is common to start the interview with an open 
ended question [72, 73]. Two examples of open-ended questions are:  
“Do you have a headache? Tell me about it, and how it affects your life.” 
“Can you describe your headache, and how you cope with it?” 
The open-ended questions are then followed by specific, close-ended headache 
questionings. These questions cover age at headache onset, location, character, intensity, 
duration, frequency and time of the headache attack. Additionally, the doctor ought to know 
about associated headache symptoms, premonitory and aura symptoms, postdrome 
symptoms, as well as relieving and worsening factors [72, 73].  
Before continuing to a physical and neurologic examination, warning signs that may indicate 
the presence of a secondary headache (Table 5) must be identified [41]. Presence of a 
warning sign mandate further investigation with neuroimaging [41, 58]. Many consider a 
complete neurologic work-up and examination of every patient presenting with a headache 
unnecessary, and the interview with examinations could be tailored to every patient [57, 
72].  
 
After the examination, the traditional headache consultation continues with prospective 
additional investigations, headache diagnoses, and non-pharmacological and 
pharmacological treatment [41, 72]. Figure 4 shows a flow chart of a normal in-person 




Figure 4 An algorithm for a traditional in-person headache consultation [72]. 
 
2.2.2 Telemedicine headache consultations 
To consider telemedicine we need to know what it is, and what it is not. Although, 
telemedicine is not a new concept, the evolving technology has made it better and more 
available over time. The first definition of telemedicine was made by Bird in 1971 [74]. He 
defined telemedicine as “the practice of medicine without the usual physician-patient 
confrontation via an interactive audio-video communication system.” In a review of the 
literature from 1970-2006, the authors found 104 definitions of telemedicine [75]. These 
reflected different perspectives; the medical, the technological, the spatial and the benefit 
perspective [75]. In my own experience, telemedicine is basically like a traditional 
consultation, but without the patient being physically present. Use of information and 
communication technologies in research is comprehensive, and a PubMed research revealed 
23536 hits for “telemedicine” pr. April 26, 2017.  
 
In this trial, we defined telemedicine as consultations that had a two-way video- and audio 
communication between the neurologist and the patient. Such headache consultations have 
an indirect online relationship rather than a direct in-person relationship.  
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Having online patient-doctor relationships have both advantages and disadvantages. The 
indirect contact between the doctor and the patient creates both a physical and a 
psychological distance (the virtual space) [76], which neurologists can use to the benefit of 
their patients. The physical distance provides a feeling of safety, a more objective 
observation, a more direct, straight forward conversation and feedback from the patient 
[76]. The psychological distance is considered as the most important part of the virtual 
space. The less doctor authority in telemedicine gives the patient more control, and in case 
of any inconvenience the patient can simply “hang up” to end the consultation [76]. 
Additional benefits of telemedicine, such as less travel, less expenses, easier access to 
headache specialist, less geographical disparity and high family and patient satisfaction make 
telemedicine more patient centered as compared to in-person traditional consultations [77]. 
One major downside of telemedicine is the difficulties in performing a full neurologic 
examination. A study of 17 patients with neurologic disorders showed that a tailored 
neurologic examination via telemedicine is possible when more than one observer is 
present, but this finding needs further investigation by including more patients and 
performing full neurologic examinations [78].  
 
2.3 Basic theory of economic evaluation  
Health economics play an important part in documenting value for money, in decision 
making processes, as a starting point for health business models, and in payment for health 
services when new technology is implemented into clinical practice [8, 79]. To understand 
the role of economics in the management of different health conditions, neurologists need 
to have basic knowledge about economic evaluation [8]. To make health economic research 
more homogenous and easier to follow, it should follow a certain pattern, and be based on 
reporting statements, such as the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement [80].  
 
Economic health evaluations analyze the costs and health benefits/efficiency of a new 
technology or treatment compared with one or more older treatments [81]. Its basic 
components are costs and health related outcomes. Costs can further be divided into 
different categories:  
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- Direct costs, such as medication and hospital costs, are related to management of a 
disease or disorder. Indirect costs are related to the reduced work capacity due to 
morbidity and/or mortality.  
- Tangible costs are those that straightforward can be expressed in monetary units, 
while intangible costs are those, which are difficult to quantify in monetary values 
(for example costs related to quality of life) [8, 82]. 
 
Additionally, it is common to divide costs into medical and nonmedical categories. 
Likewise, there are many types of cost evaluations. The most common types that are used in 
health economics are cost minimization analysis, cost-effectiveness analysis, and cost-
benefit analysis [82].   
 
Cost minimization analysis evaluates only the costs of two or more interventions. This kind 
of analysis is used when the studied interventions are otherwise considered equally efficient 
[8, 79, 82].  
 
Cost-effectiveness analysis compares clinical outcomes and costs of different interventions. 
Its goal is to identify equal or more benefits of an intervention at lower costs for a certain 
given disorder (e.g. migraine) [79]. The costs are divided by the effect, which is measured in 
one dimensional units (e.g. headache days) [79]. This is done by calculating an Incremental 
Cost Effectiveness Ratio (ICER) [81, 83]. ICER is the cost/effect of one intervention divided by 
the cost/effect of another (∆Cost/∆Effect) [81, 83]. It is common to show a graphical 
illustration of the difference in cost effectiveness between an intervention and the control 
(Figure 5) [81, 83]. In figure 5, the existing control intervention is preferred in quadrant 4, 
and the new intervention dominates in quadrant 2. Since the new intervention is less costly 
and less effective in quadrant 3, and both more costly and effective in quadrant 1, an ICER 
needs to be calculated. The accepted ICER threshold depends on the intervention and health 
outcome that is studied.  
 
Cost-utility analysis is a kind of cost-effectiveness analysis that applies natural units to 
benefits. This enables comparisons between treatments of different diseases [8, 79, 82]. 
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Quality Adjusted Life Year is the most commonly used parameter. It ranges from 0 (worst 
state) to 1 (best state) per year after the intervention/treatment [79, 82].  
In cost-benefit analysis, benefits are transposed into monetary units, and aims to find 
positive net benefits (benefit minus cost) [79].   
The methods of economic evaluations are being debated, and there is often uncertainties 
regarding the data [84]. Sensitivity analysis could be performed to cope with some 
uncertainties in the variables and the conclusions that are made, but maintaining 
transparency is also important [79, 84]. 
 
 
Figure 5 The cost-effectiveness plane based on Petrou and Gray [81].  C is the comparator 





2.4 Basic actor-network theory 
Since implementation of telemedicine for headache patients can be viewed as an 
informational infrastructure that is in use in our department, I would argue that actor-
network theory makes a good fit to analyze different aspects of the information and 
communication infrastructure. In the general discussion of this thesis (7.6 Telemedicine 
dynamics and 7.7 Future perspectives), actor-network theory will be used to analyze the 
present situation and possible future implementation of telemedicine for headache patients 
in clinical practice. Actor-network theory may help us analyze the borders between the 
technological and social aspects [85]. It can help to analyze and describe how previous and 
current status of both the interactions in the networks between paper based patient 
records, electronic patient records, telemedicine technology and the travelling patients and 
neurologists work and adopt to each other; to get a better understanding of what kind of 
negotiation is going on in the “eco-system”. Furthermore, it can help to analyze how 
implementation of a shared electronic patient record and telemedicine consultation would 
influence the environment of a neurologic outpatient practice.   
 
Actor-network theory, which is born out of science and technology studies, is regarded as 
both a theory and a methodology used to analyze and describe informational 
infrastructures, i.e. the connections (network) between technological and non-technological 
elements and the dynamics in how these elements work together [86]. All networks contain 
both humans and technology. Actor-network theory provides a vocabulary we can use to 
describe informational infrastructures: the borders and boundaries between the social and 
technology, its interactions and the negotiation that is going on in these networks.  
 
Some key concepts in actor-network theory are: actor or actants, inscription and translation, 
program and anti-program, irreversibility, black-boxing or black-box, delegates, enrollment, 
momentum and alignment [86, 87]. Actors can be both humans and non-humans. Non-
humans are referred to as technological artefacts or equipment. Sometimes non-humans are 
named actors, but a more proper term could be actants [86, 87]. Actants could also be used 
to differentiate non-humans from humans. Inscription and translation are considered as key 
concepts in actor-network theory [86]. Inscription refers to how a technical artefact makes 
an action; i.e. how it generates a pattern of use. The stronger the inscription, the more likely 
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a user will follow a given pattern of use and vice versa. Translation may be viewed as the 
process of how an inscription is made, how we intend to align a technical artefact. To follow 
a program means to use a system or equipment in an anticipated way. If something is used 
in an unanticipated way, we follow an anti-program.  
 
Four important aspects of inscription and translation in actor-network theory are, 
“Standardization, id. of all anticipations (scenarios) held by the various actors, materials of 
the inscriptions; how anticipations are translated and inscribed into standards, who inscribes 
them and strength and weaknesses of the inscriptions; what it takes to work around them or 
oppose them” [86].  
 
In a description of the biologists’ network in the scallop industry of St Brieuc Bay, translation 
was divided into four parts: problematization, interessement, enrollment and mobilization 
[88]. Problematization defines the problem, identifies the actors and the program made to 
solve the problem. By interessement the actors tries to engage other actors, giving them 
different roles and tasks in the network. In the enrollment phase, roles are defined and given 
to actors. In mobilization, primary actors use different methods to represent other actors in 
the network. The author concludes: “Translation is a process before it is a result”, and the 
result is that some actors end up controlling others and translation may fail. The paper 
demonstrates that actor-network theory is a well suited method to identify and analyze 
power relationships [88].  
 
Enrollment Components in an Actor-network theory are in alignment when they cooperate 
to achieve a common goal, and a network that is aligned is also stable. Alignment happens 
through enrollment. Delegates mean actors or actants with special viewpoints inscribed [87]. 
Irreversibility shows how difficult it is to change an actor network element and how prone it 
is to changes from other translations [86]. In other words, it gives a scale for the elements, 
and shows a level where it is not possible to choose a different path or direction [87]. The 
black-box refers to all the invisible elements of an actor network that works properly [87, 
89]. When a system works properly, we only see the inputs and outputs of the “black-box”, 
and not how the input and outputs actually are created (we do not see the often complex 
system within) [87, 89]. The complex system within only appears for users upon a system 
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failure or breakdown, i.e. when there is inadequate input and/or output [90]. The 
momentum shows how problematic it is to stop a process. When a process/program gains 
momentum it may become almost impossible to stop it, and only a catastrophic or historical 
event may stop it [86]. Internet is a common example of a software that has gained 
momentum [62].  
 
The actor-network theory does not distinguish between humans and non-humans, neither 
does it distinguish between microphenomena and macrophenomena [85, 86]. I would 
therefore argue that it is not a well-adapted method to analyze ethical issues [85, 86]. 
Although the actor-network theory does not differentiate between humans and non-
humans, it recognizes each individual as different, as well as each technology as different 
[85].  
 
Because of the tight relationships and negotiations between the actors and actants in actor-
network theory, introduction of a new actor or actant often leads to realignment or 
influence on the other actors/actants [91]. The same applies if an actor or actant is replaced 














3. AIMS OF THE STUDY 
My aim in this thesis is to determine whether telemedicine in the treatment of nonacute 
headache patients is a good alternative to traditional in-patient consultations. In order to 
achieve this, different perspectives of telemedicine consultations were investigated:           
- Whether telemedicine is accepted among patients with headaches (Paper I).  
- Whether telemedicine consultations for headaches are cost-saving (Paper I). 
- Whether the management of headache patients via telemedicine is technically 
feasible (Paper I). 
- Whether headache patients are satisfied with a telemedicine consultation (Paper II 
and III). 
- Whether the treatment of headache patients via telemedicine is efficacious (Paper II 
and IV). 
- Whether the management of nonacute headache patients via telemedicine is safe 
(Paper IV). 
- Whether the management of nonacute headache patients via telemedicine is cost-
effective (Thesis). 













4. PATIENTS AND METHODS 
4.1 Trial design 
To evaluate different aspects of telemedicine consultations for nonacute headaches, we 
conducted a prospective, single center, unblinded, randomized and controlled non-
inferiority trial. Telemedicine consultations were compared to traditional in-person specialist 
consultations.  
 
4.2 Eligibility criteria 
The participants were Norwegian-speaking patients, aged 16-65 years, who were referred to 
our neurologic outpatient department for diagnosis and/or treatment of a nonacute 
headache. In Norway the age of consent is 16. Nonacute headache was defined as a 
headache that had occurred at least four weeks before referral, and without clinical or 
radiological signs of structural intracranial pathology causing the headache as reported by 
the referring general practitioner [92]. This definition, together with recruiting from a 
working population not older than 65, was considered as sufficient to exclude the presence 
of secondary headaches (except MOH). To prevent recruiting already consulted and 
diagnosed patients, those who were evaluated for headache by a neurologist two years prior 
to the referral letter were not included. To avoid outdated information, the waiting time was 
set to no more than four months from the date of the referral letter. When in doubt for 
inclusion, the patient was discussed in a meeting between two neurologists (KIM and SIB).  
 
4.3 Study population and patient administration 
From September 30 2012 to March 30 2015 we included, randomized and consulted 402 out 
of 557 nonacute headache patients referred to our neurologic outpatient department 
(Figure 6). The participants were patients from the three northernmost counties in Norway; 
Finnmark, Troms and upper Nordland, as well as from Svalbard. The area of inclusion 
corresponds to the area of coverage for the Department of Neurology at the University 
Hospital of North Norway in Tromsø city, and is shown in figure 2. Apart from one 
neurologist in Harstad city, the department in Tromsø is the only neurologic service in 
Finnmark, Troms and upper Nordland County, and the travel distances to other neurologic 
departments are extensive.  
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During the inclusion period, a neurologist (KIM) daily screened referral letters to the 
Department of Neurology in Tromsø University Hospital for eligible candidates. The referral 
letters were located in the Distributed Information and Patient System for hospitals (DIPS 
ASA, Bodø, Norway) [65, 93, 94]. If a patient met the inclusion criteria, a study coordinator 
sent an information letter to the patient. Then, she called the patient to check whether the 
patient met the inclusion criteria, and whether the patient accepted telemedicine and 
wanted to participate. If the patient agreed to participate (orally), the study coordinator sent 
an invitation letter, a consent form, and a questionnaire (Appendix III). These patients got 
included in the project. If the patient did not give consent, the referral letter was returned to 
the neurologist (KIM) who evaluated the application for an ordinary in-patient visit at the 
department. 
 
All participants met at the neurologic outpatient department in Tromsø city, and were taken 
care of by a study nurse at the neurologic treatment unit. The nurse checked the 
participants’ pre-filled questionnaire (Appendix III), measured height, weight and blood 
pressure, and randomized the participant by calling the external randomization office at the 
research department at the hospital in Tromsø. Every phone call was made between 9:00 am 
and 15:00 pm. After randomization, a nurse followed each participant to the appropriate 
consultation room. Patients were either followed to a video-conference room located just 
outside the Department of Neurology, or to an examination office located in the 
department. The pre-filled questionnaire consisted of questions about social and family 
history, medications, alcohol, smoking, physical exercise and headache influence on daily 
life.  
 
The neurologists (KIM and SIB) consulted patients from the telemedicine- and traditional in-
patient group from the same examination offices at the Department of Neurology. All 
consultation fees were waived for patients who participated in the study.   
To ensure no physical contact between the neurologists and the patients in the telemedicine 
group, these patients were kept out of sight of the neurologist. The consultations took place 




All patients had a one-time consultation, which in both groups consisted of a structured 
interview without neurologic examination (IV). The telemedicine consultations were 
performed in the same manner as the traditional in-patient consultations. They all started 
with open-ended questions before the structured questions.  
 
The structured questions (Appendix IV) consisted of  
- Age at onset and headache duration,  
- Location and character of the headache(s),  
- Duration, frequency and timing of the headache attacks, 
- Pain intensity and headache influence on daily life, 
- Precipitating and aggravating factors, 
- Premonitory and aura symptoms, 
- Associated headache features. 
 
Secondary headaches were rechecked and differentiated from primary headaches by 
rechecking red flags (Table 5) and neuroimaging. The consultations ended with diagnosing 
the specific headache disorders according to ICHD-2, ordering investigations, starting 
treatment (education, advice, medication) and scheduling follow-up.  
At three and 12 months, the study coordinator sent a questionnaire to every participant. The 
questionnaires were sent out by patient preference, either in an ordinary letter mail, or 
through an internet survey system (Questback [95]). The coordinator sent a reminder to 
participants who did not answer within two weeks. A flow chart is provided in figure 6.   
 
4.4 Randomization 
Randomization was performed by the randomization office in the research department at 
Tromsø University Hospital, which was an external party not otherwise involved in the study. 
The concealed block randomization was computer generated by the use of an Rnd function 
in Microsoft access (Redmond, WA) [96]. The block sizes ranged between four, six and eight. 





4.5 Interventions and infrastructure 
The telemedicine consultation was a two-way encrypted video- and audio communication 
between the neurologist in the examination room at the Department of Neurology and the 
participant in the videoconference room located just outside the department.  
 
The information and communication equipment consisted of the following technology:  
Cisco (Moorestown, NJ) C40 Integrator Package, Cisco C40 Integrator Multisite, Cisco 
Precision HD 1080p 12xcamera, an NEC X551s 55-inch light-emitting diode (LED) monitor, 
Audio-Technica ceiling microphones and JBL LSR2325P active speakers, Integrator Package 
C40 Dual Display option and a Cisco Touch-Control Device for C Series. This equipment is 
installed in one office (Figure 7). The neurologist consulted the patients from two other 
examination rooms via a Cisco EX60 unit with an InTouch panel (Figure 1 and 8).  
 
4.6 Data collection and questionnaires (Papers I – IV) 
Data was collected from the referral letters (Appendix II), from telephone interviews prior to 
the inclusion (Appendix I), from a questionnaire prior to the consultation (Appendix III), from 
the consultation (Appendix IV), from follow-up questionnaires at three and 12 months 
(Appendix V and VI, respectively), and from the electronic patient hospital records in 
Northern Norway. Additionally, a hospital economist collected data on travel expenses from 
the Norwegian patient travel agency (Pasientreiser) (Appendix VII) [97]. Estimated patients’ 
salary was based on data from Statistics Norway (Paper I).  
 
In all papers, baseline characteristics were collected from the referral letter, from the 
telephone interview, from the questionnaire prior to the consultation, from the consultation 













Figure 7 Telemedicine Infrastructural Setup at the Department of Neurology in Tromsø 




Figure 8 Telemedicine Infrastructural Setup at the Department of Neurology in Tromsø 




4.7.1 Headache diagnosis and measurements 
Diagnosis of headache was made by a structural clinical interview at the consultation 
(Appendix IV). Patients were diagnosed according to the International Classification of 
Headache Disorders-2 (ICHD-2) [22]. In case of more than one headache disorder in a 
patient, data for this study were primarily evaluated for the most prominent headache. The 
most prominent headache was defined as the headache that had the most significant 
influence on the patients’ daily life.  
 
The Headache Impact Test-6 (HIT-6) questionnaire was developed from 54 preexisting 
headache impact test questions and 35 questions from clinicians in 2003 [98]. It is a 
headache specific patient outcome measure designed for use in both clinical practice and 
research to quantify the severity of headache influence on patients’ daily life [98]. The 
questionnaire is made of 6 items regarding the intensity of the headache, its influence on 
work and social activities, and the association with fatigue, irritation and concentration. Each 
question has five answers (“Never”, “Rarely”, “Sometimes”, “Very Often” and “Always”), and 
each answer scores 6, 8, 10, 11 or 13, respectively. A score of 50 or higher is considered high, 
and suggests contact with a physician.  
 
In this trial, Baseline HIT-6 measures were used in all papers. In paper II, we used HIT-6 three 
months after the consultation and calculated change from baseline. In paper III, we 
constructed a variable that showed the between-group minimally important difference in 
HIT-6 (2.3 points) change 12 months after the baseline consultation [99]. In paper IV, we 
used mixed between-within participants ANalysis of Variance (ANOVA) to assess change in 
HIT-6 across three time periods (at baseline, three and 12 months). Additionally, in paper IV 
we constructed a variable that showed change in HIT-6 from baseline to 12 months, and 
calculated HIT-6 from the 12-month questionnaire.  
To measure headache intensity, we used a Visual Analogue pain Scale (VAS) together with its 
numerical counterpart at baseline. Only the numerical scale was used in the questionnaires 





We used VAS at baseline in all papers. In paper II, we used VAS as a headache intensity 
measure three months after the consultation and calculated change from baseline. In paper 
III, we constructed a variable that showed the minimally important difference in VAS (we 
chose 1.3 points based on previous literature) change 12 months after the baseline 
consultation [100-102]. In paper IV, we used mixed between-within participants analysis of 
variance to assess change in VAS across baseline, three and 12 months. Additionally, in 
paper IV we constructed a variable that showed change in VAS from baseline to 12 months, 
and collected VAS from the 12-month questionnaire.  
 
We divided headache frequency into three groups: < 7 days, 7-14, and ≥ 15 days per month 
within the last 3 months [22] before the baseline consultation. Headaches occurring < 7 days 
per month were defined as low frequency episodic headaches, 7-14 days per month as high 
frequency episodic headaches, and chronic headaches as having ≥ 15 headache days per 
month in the three months before the baseline consultation and questionnaires. Headaches 
occurring 7-14 days per month have previously been shown to have increased risk of 
medication overuse headache [103]. These three categories were used in paper I, II and IV. 
In paper III, headache frequency was divided into < 15 days and ≥ 15 days. 
 
Additionally, at baseline patients were asked if the headache had changed while waiting for 
the specialist consultation, and at three and 12 months they were asked if the headache had 
changed in the wake of the consultation: “Is the headache better, unchanged, or worse?”, “Is 
the headache frequency reduced, unchanged, or increased?”, and “Is the headache intensity 
reduced, unchanged, or increased?”. From the questionnaires at three and 12 month, we 
constructed a categorical variable to show if patients were subjectively better, unchanged or 
worse from their headache.  
 
4.7.2 Satisfaction measurements 
Acceptability of telemedicine was evaluated by a telephone interview of eligible candidates 
made by a study coordinator (Appendix I). The candidates were asked if they accepted 
telemedicine visits or not. Answers were coded as a categorical binary variable denoting 
feasibility of telemedicine (“Yes” or “No”) as reported in paper I.     
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At each telemedicine consultation, the neurologist asked participants if they were satisfied 
with the video- and audio quality. These answers were categorized into two binary variables 
(“Yes” or “No”) as reported in paper I. 
 
All participants received a questionnaire at three months. They were asked if they were 
satisfied with the consultation three months earlier (“Yes” or “No, why not?”). All 
participants received another questionnaire at 12 months. Participants were asked if they 
were satisfied with the consultation 12 months earlier (“Yes” or “No”). Additionally, 
participants were asked if they were satisfied with the communication, information, 
diagnosis, advice and medication at the specialist consultation 12 months earlier (“Yes” or 
“No”), and what kind of consultation form they preferred in light of the consultation 12 
months earlier (“traditional”, “telemedicine” or no “preference”.  
 
Satisfaction with consultation was evaluated as a categorical binary outcome measure at 3 
months (Paper II) and at 12 months (Paper III). To ensure a more dynamic long-term 
evaluation of satisfaction, we additionally constructed a variable of patients who were 
satisfied at both three and 12 months (Paper III). Participants satisfied with communication, 
information, diagnosis, advice and medication were evaluated as categorical binary outcome 
variables (“Yes” or “No”) at 12 months (Paper III).  
All satisfaction variables are listed in table 6.  
 
4.7.3 Cost and travel measurements 
In paper I, data from the Norwegian Patient Travel Agency regarding patient travel expenses, 
and the agencies probabilistic method of calculating the least expensive means of travel, 
were obtained and used for travel cost evaluations [97] (Appendix VII). A hospital economist 
provided these data (Appendix VII). Patients’ incomes were calculated from the Norwegian 
full-time employee’s average salary (€4.681 per month in 2014) [104]. We defined 
economical loss for patients from urban areas (in Tromsø), having travelled plus being 
consulted < 3.5 hours, as half a day’s salary. The loss for patients from rural areas (outside 
Tromsø), spending > 3.5 hours on travel and consultation, was defined as one day’s salary. 
All costs were adjusted to the consumer price index (CPI) per January 1, 2015 from Statistics 
Norway, and Norwegian kroner were converted into euros by using the exchange from the 
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Norwegian Bank on December 31, 2014. Traveling distance in kilometers, and traveling time 
in hours, were estimated by Google Maps and controlled with maps available from the 
Norwegian yellow pages [105]. When these programs failed to calculate a distance, we 
measured it manually on Google Maps. Cost and travel variables are summarized in table 6.  
 
4.7.4 Feasibility measurements 
These variables were constructed from a telephone interview (acceptability), and from data 
registered during the consultation (Paper I). Additional feasibility variables that concern 
quality and safety were retrieved at three and 12 months. Feasibility variables are listed in 
table 6.  
 
4.7.5 Safety aspects and measurements 
As reported in paper IV, the electronic patient records from all hospitals in Northern Norway 
were thoroughly reviewed for safety outcomes, from the first document to one year after 
the specialist headache consultation, and these were compared to information given by the 
participants in both the three and 12-month questionnaire (for the presence of secondary 
headaches, neuroimaging, lumbar puncture results and other test results). The variables we 
















Table 6 Variables from the interview, the pre-consultation, consultation, 3 and 12-month 
questionnaires and patient medical records to assess telemedicine feasibility for nonacute 
headaches*. 




Travel distance (km) 
Travel distance (hours) 
Acceptability  
 
Satisfied with video 
and audio quality 
 
Satisfaction at 3 and 
12 month 
 


























Number of GP visits at 3 
and 12 months.  
 
Number of neurologist 
visits at 12 months. 
 
Presence of secondary 
headache at 12 months. 
 
Major MRI/CT 
abnormalities at 12 
months. 
 
CSF pathology at 12 
months. 
Dropout, medical reasons 
 




Preparation to visit (min)  
 
Visit time (min) 
 
*Apart from Cost/Travel values, which were presented as median (range), the other values 
were presented as n (%) for categorical or mean (SD) for continuous variables.  
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4.8 Statistical analysis 
A pre-study power analysis was performed to calculate a 15% non-inferiority margin (∆) of 
binary satisfaction variables. This limit was chosen based on literature [106].  
To calculate sample size we used 1% significance level (alpha) and 95% power (1-beta). 
According to a questionnaire-based study, approximately 50% of participants in northern 
Norway were satisfied with their headache specialist consultation [107]. Based on this, and if 
there is no difference between the in-person consultations and telemedicine, we would 
need 351 headache patients in each group to achieve enough participants to exclude a 
difference of more than 15%. Because the share of satisfied patients in previous 
telemedicine studies are reported above 90% [108], we made an interim analysis for the first 
40 participants regardless of group setting. The share of satisfied participants was 92.5%. 
Based on this, we expected satisfaction as being 90% in each group. If there is truly no 
difference between the standard in-person traditional consultations and telemedicine, then 
“127 headache patients are required to be 95% sure that the upper limit of a two-sided 
confidence interval (or equivalently a 99% one-sided confidence interval) will be sufficient to 
exclude a difference in favor of the traditional group of more than 15%” [109]. By 
anticipating dropout, and to ensure enough participants throughout the study, we enrolled 
402 headache patients. 
 
Data was analyzed with version 21 of the Statistical Package for Social Science (SPSS) in 
paper I and II, and version 23 was used for paper III and IV.  
 
We checked continuous variables for normal distribution with the Shapiro-Wilk test, 
skewness, kurtosis as well as visual inspection of histograms, Q-Q plots, and box plots. The 
independent samples T test and Mann–Whitney U test conclusions agreed for all continuous 
variables in all papers. For a normal distribution, we defined the Shapiro-Wilk test P value 
above 0.05, skewness and kurtosis as being somewhere between -1.96 to 1.96, and 
histograms, Q-Q plots and box-plots should visually indicate a normal distribution. 
Continuous variables with normal distribution were primary compared with independent 




In paper I, normally distributed variables were given in mean with standard deviation (SD), 
and non-normally distributed as median with range. For consistency reasons, all continuous 
variables were given in mean (SD) in paper II, III and IV. Additionally, in large samples the 
statistics that we used are considered tolerant for violation of the normality assumption. 
Categorical variables were compared with Chi square test, and are presented as numbers 
and percentages in all papers. Yates continuity correction was used for 2 ×2 tables. All tests 
were two-sided. Statistical significance was defined as p < 0.05.  
 
Variables in the papers are labelled prespecified or non-prespecified. At three and 12 
months, we performed both per-protocol and intention-to-treat analyses. Last observations 
carried forward (LOCF) for continuous variables and chi-square cross-tabulation with missing 
values for categorical variables were used for performing the intention-to-treat analyses.  
 
The seven patients who were excluded after randomization did not take part in the 
intention-to-treat analyses. These patients were included in the other excluded patients, and 
accounted for by comparing participants with those who were not found eligible for the 
study.  
 
In paper I, we made two hierarchical multiple regression models to assess the ability to 
predict VAS and waiting time for rural patients when adjusted for age, sex and other 
variables. All variables in the models were first tested in univariate analysis. Apart from sex 
and age, only variables associated with changes in pain scores in the first model, or could be 
associated with changes in waiting time in the second model, were used. The nonparametric 
variable waiting time was log transformed. To check for outliers, variables were controlled 
with normal probability plots (P-P) of the regression standardized residuals, histograms, and 
scatterplots for normality, linearity, and residual independence. Multicollinearity was 
checked by tolerance and variance inflation factor (VIF) in both models 
 
In Paper I, study participants’ age and sex were compared to patients who were not eligible 
for the study. In paper III, we compared demographics and clinical characteristics of 
participants who answered the three and 12-month questionnaire with participants who did 
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not answer. Baseline and clinical characteristics of participants were also compared with the 
same data from non-respondents in paper III.   
 
4.9 Ethics 
The patients’ privacy, physical and mental integrity have been safeguarded in accordance to 
the ethical principles in the Helsinki Declaration [110] and to the principles outlined in the 
Norwegian Code of Ethics for Doctors [111].  
 
All of the participants’ informed consents were obtained before data collection began. 
Participants could withdraw from the study at any time, and without any specific reason 
given. Withdrawal would not affect the patients’ further treatment or follow up. The 
Norwegian National Committee for Medical and Health Research Ethics (REC), number 
2009/1430/REK approved the study.   
 
The trial was first registered, and its progress was yearly reported, at the Norwegian 
Research and Management database (FAS, ID3897/HST959-10 and HST1216-14) [112, 113]. 
 
As explained earlier, the trial overlaps with a project in a small rural hospital in Northern 
Norway from 2009. Due to reorganizations, lack of time to research, and difficulties in 
patient recruitment in the smaller hospital, the study was stopped and reorganized. At that 
time, the researchers considered telemedicine consultations as research on health services, 
and did not regard it as being a study that required registration according to International 
Committee of Medical Journal Editor’s (ICMJE) definition in 2008 [114]. Therefore, it was 










5. SUMMARY OF RESULTS 
5.1 Paper I 
In this study we demonstrated the acceptance, cost-savings and technical feasibility of 
telemedicine for consulting nonacute headache patients. Out of 479 eligible patients, we 
found that 402 (83.9%) accepted telemedicine consultations (Figure 6). By using the 
Norwegian patient travel agencies probabilistic method of finding the least expensive public 
travel, and Norway Statistics average salary, we estimated that consultations were most 
expensive for patients living in rural areas (median travel cost €249 (range 409) and loss of a 
day’s salary (€234).  
 
To evaluate the technical feasibility, the 402 patients that accepted telemedicine took part in 
an intervention study, and were randomized to receive either a telemedicine or a traditional 
in-person visit. All telemedicine patients were satisfied with the video quality and 198/200 
(99%) were satisfied with the sound. There were some minor technical errors (21/200, 
10.5%), which did not influence the consultations significantly. However, one drop out was 
caused by a technical error. The telemedicine consultations were 5 minutes (11%) shorter 
than the traditional visits (P < 0.001). We found no differences in the consultation 
parameters (investigations, advice, prescriptions and GP and neurologist follow-up 
appointments) (P > 0.05) between the randomized groups. 
 
Fewer women were referred from rural areas as compared to urban (P = 0.04), and women 
from rural areas had higher VAS intensity score than those from the urban areas (P = 0.01). 
Patients from the rural group waited longer for specialist consultations than those in the 
urban group (P = 0.001).   
 
In summary, we documented that telemedicine is highly acceptable, provides significant cost 









5.2 Paper II 
Based on the cohort described in paper I, we wanted to determine whether telemedicine is 
non-inferior to traditional consultations in patient satisfaction and treatment efficacy at 
three months. We postulated that the share of satisfied patients in the telemedicine group 
at three months should be not less than ≤ 15% of the share in the traditional group.  
 
The satisfaction rate was 158/178 (88.8%) in the telemedicine group and 156/169 (92.3%) in 
the traditional group (-3.5% difference with standard error). Figure 9 shows the share of 
satisfied patients in the two randomized groups. A two sided 98% confidence interval for the 
difference of these two proportions is -0.11 to 0.04 = -11% - 4% [115, 116]. The lower 
boundary of the confidence interval for the difference is above the prespecified -15% limit of 
non-inferiority.  
 
By using per-protocol and intention-to-treat analysis, we found no statistical difference in 
treatment outcomes (HIT-6, VAS, subjective headache change, headache days per month for 
the last three months, use of painkillers and triptans, diagnostic recall, compliance and work 
status) between telemedicine and traditional consultations at 3 months (P > 0.05).  
 
A non-prespecified per-protocol subgroup analysis of rural patients showed that fewer 
shares of participants who underwent telemedicine visited their general practitioner within 
three months after the baseline consultation (P = 0.002), and those who underwent 
telemedicine had less general practitioner headache visits (P = 0.003). The conclusions of 
these per-protocol analysis coincided with the intention-to-treat analysis. 
At baseline, and in patients who answered at three-months, women were younger than 
males (p = 0.001 and 0.001), and had more years of education (p = 0.02 and 0.02). 
 
In conclusion, this study demonstrates that a telemedicine consultation is non-inferior to an 






Figure 9 A Per-protocol analysis showing the share of satisfied patients in telemedicine and 








Figure 9 B Intention-to-Treat analysis showing the share of satisfied patients in telemedicine 











5.3 Paper III 
In this 12 month questionnaire based follow-up our aim was to confirm the three months 
satisfaction results from paper II. Additionally, we wanted to investigate different aspects of 
telemedicine satisfaction and patients’ consultation preferences.   
 
The share of patients who were satisfied at both three and twelve months was 124/145 
(85.5%) in the telemedicine group and 118/134 (88.1%) in the traditional group (Figure 10). 
This is a -2.6% difference with standard error. The 98% confidence interval is -0.12 to 0.07 = -
-12% to 7% [115, 116], which is above the prespecified non-inferiority limit set at -15%.           
 
The share of patients who were satisfied at twelve months was 134/151 (88.7%) in the 
telemedicine group and 127/140 (90.7%) in the traditional group (-2.0% difference with 
standard error). The 98% confidence interval for the differences is from -0.1 to 0.07 = -10% 
to 7% [115, 116]. The lower boundary confidence interval is -10%. This is above the 
prespecified non-inferiority limit set at -15%. 
 
We found no difference in patients’ satisfaction with communication, information, diagnosis, 
advice and prescriptions between the telemedicine and traditional group (P > 0.05).  
 
In the telemedicine group, 99/147 (67.3%) headache patients were indifferent to the 
consultation form as compared to 42/138 (30.4%) in the traditional group (P = 0.001 for per-
protocol and intention-to-treat analysis).  
 
There was a higher share of women satisfied with communication in the telemedicine group 
(P = 0.027 and 0.001 for per-protocol and intention-to-treat, respectively). In the intention-
to-treat analyses, a higher proportion of women were satisfied with information, diagnosis, 
advice and medication and a higher share were overall satisfied in the telemedicine group (P 
< 0.05), but the per-protocol analyses did not concur with these results (P > 0.05).  
 
In conclusion, the long-term satisfaction with a telemedicine consultation is not inferior to a 





Figure 10 A Per protocol comparison between telemedicine and traditional headache 
consultations of patients who were satisfied at both 3 and 12 months (confirmed satisfied) 






Figure 10 B Intention-To-Treat analysis comparison between telemedicine and traditional 
headache consultations of patients who were satisfied at both 3 and 12 months (confirmed 
satisfied) and those who were unsatisfied at both 3 and 12 months (not confirmed satisfied),  







5.4 Paper IV 
In this paper, we further elaborated on the efficacy and quality, to evaluate the treatment 
efficacy and safety of telemedicine within one year after the specialist consultation. We used 
a mixed between-within patients analysis of variance for assessing differences in headache 
influence on daily life (Figure 11) and headache intensity between telemedicine and in-
person consultations. With a significance level of 0.05 and 95% confidence intervals we 
found no differences in HIT-6 or VAS between the two groups assessed over three time 
periods (at consultation, at three months and at 12 months), F (1, 271) = 0.043, p = 0.84 and 
F (1, 255) = 0.22, p = 0.64 for HIT-6 and VAS, respectively. At 12 months, the telemedicine 
and traditional visits were not different in patients subjective headache change, headache 
days per month, frequency in the use of pain-killers, triptans and prophylactic headache 
medications, diagnostic recall and frequency of general practitioner visits due to headache (P 
> 0.05).  
 
By reviewing the questionnaires and every participant’s electronic patient record in all 
hospitals of Northern Norway, we identified one secondary headache in each randomized 
group. Patients in both groups showed no differences in pathological findings on 
neuroimagings and cerebrospinal fluid analysis, or in compliance to treatment and frequency 
of specialist visits and hospitalizations (P > 0.05). 
 
After one year of follow-up, telemedicine treatment efficacy and safety is non-inferior to 






Telemedicine visit  Traditional visit  
             
Time period  n Mean SD  n Mean SD 
At consultation 142 63.7 6.5  131 63.6 6.1 
At 3 months  142 60.4 8.6  131 60.0 7.4 
At 12 months 142 59.8 9.2  131 59.9 8.2 
            
Abbreviations, SD; Standard Deviation 
Figure 11 A prespecified mixed between-within patients ANOVA of HIT-6 (P=0.84) at 3 time 
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6. METHODOLOGICAL CONSIDERATIONS 
6.1 Study design  
The randomized controlled trial (RCT) is like a classic experiment, in which patients are 
allocated at random to either an experimental or a control intervention, and in which the 
independent variables are manipulated on. RCT is considered as the gold standard method 
for investigating effects of presumed preceded causes (causality) [117, 118]. Proper 
concealed randomization minimizes the risk of systematic errors, which will be discussed in 
the next section.  
 
In the present trial, eligible participants gave informed consent before randomization. To 
include more patients, we could have asked for consent after randomization, and only get 
consent from patients who underwent the telemedicine intervention, arguing that the other 
group would get a traditional consultation anyway (as in Zelen designs) [119]. A downside 
would be the possibility of telemedicine patients crossing over to traditional consultations, 
which would dilute the endpoints and bias the intention-to-treat analysis. Since only 10% of 
the eligible patients declined telemedicine and participation in this trial, the consent prior to 
randomization does not minimize the generalizability. Another way to increase 
generalizability, was to include a usual care “real life” control group. Due to the number of 
patients needed, this would be more time consuming and hard to achieve.   
 
A non-inferiority trial aims at determining if an intervention is no worse (non-inferior) to a 
control intervention based on a predefined non-inferiority margin [120]. This design was 
chosen due to the many potential advantages and convenient aspects of telemedicine as 
compared to traditional in-person visits (eliminate unnecessary travel, give patients more 
time, reduce both direct and indirect costs and increase access to care, especially in areas 
without headache specialists) [106, 120].  
 
The 15% non-inferiority margin was based on previous literature and clinical considerations. 
In non-inferiority studies of telemedicine, a non-inferiority margin of 10% is often considered 
as strict and 20% as liberal [106]. This margin is similar to Food and Drug Administration’s 
threshold for establishing bioequivalence [121]. To achieve an adequate amount of 
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participants, we performed a power analysis, which was followed by an interim analysis. This 
was done in order to ascertain enough enrolled participants, and to prevent unnecessary 
study prolongation if participants were unsatisfied with telemedicine. The reason for 
choosing satisfaction variables for power analysis is explained in paper II.  
 
6.2 Bias and confounding 
Bias is defined as a systematic error that occurs due to unprejudiced favoring one answer 
over another. An illustration of biases in the randomized controlled trial is shown in figure 
12. A confounder is defined as an underlying factor that affects the outcome, the mediator 
or the predictor in a causal path. 
 
The telephone interview on telemedicine acceptance and participation, and the cost analysis 
in this study (paper I) have not been derived from randomization, and should be regarded as 
equivalent to a nonrandomized cohort. Hence, the assessment of the variables from these 
methods is more prone to observation bias. To compensate for this, two well-trained study 
coordinators performed the telephone interview according to a standard work protocol 
(Appendix I). The travel cost analysis was performed by an independent experienced hospital 
economist, who obtained data from the Norwegian Patient travel Agency and calculated 
travel expenses based on their standard probabilistic method (Paper I, appendix VII). Having 
these clear, standardized procedures minimize the risk for observer bias. Other limitations of 
the cost-saving analysis have been discussed in paper I.  
 
In paper I, we controlled nonrandomized subgroups for confounders by using hierarchical 
linear regression to assess rural location as a predictor of VAS and to assess the ability to 
predict the waiting time of patients from rural locations. Travel distance and time was 
calculated by Google Maps and controlled with a function in the Norwegian yellow pages, 
which will bias the results because all patients do not travel by car. In paper II, the subgroup 
analysis of patients from urban and rural areas was non-prespecified and not randomized, 
which is more likely to give a false positive result by chance [122]. Likewise, the gender 
comparisons and telemedicine subgroup analysis of patient preference in paper III are more 




To conceal allocation as long as possible for patients and neurologists, the randomization 
was always made as the last step before patients were followed to the allocated 
consultation type. To further assure good allocation concealment, a telephone to an external 
independent party (the hospitals randomization office) was made. On that site, block 
randomization was generated in a locked unreadable computer program. A concealed 
randomization compensates for selection bias. In addition, the patients were consecutively 
recruited from those referred to our neurologic outpatient department. On the other hand, 
we only recruited eligible patients who accepted telemedicine and study participation from 
this group, but most of the interviewed eligible patients accepted both (Figure 6).  
 
Having the randomization process as the last step before consultation also compensated 
performance bias. This bias may still occur if one neurologist favors one consultation type 
over the other, being aware of the fact that studies with positive results are more likely to be 
published (citation bias) [123]. Performance bias could have disturbed the causality when 
comparing the two consultation types. To avoid any neurologist effect, we stratified on 
neurologist at randomization. Blinding can compensate for performance and also 
interviewer bias (observation bias), but would be very challenging to achieve in this trial. 
However, both positive and negative results in this trial would be valuable findings. The 
neurologists’ experience could also have effect on the outcome. On the other hand, the 
neurologists were experienced with evaluating patients with headache, and patient 
satisfaction and treatment effect were balanced and did not increase substantially over time 
in the study groups.  
 
In most studies, some patients declines participation, and others are lost to follow up. Such 
attrition is important since it may cause bias, which is not eliminated by randomization. In 
this study, most of the eligible patients accepted participation, and only 7 were excluded 
after randomization. These 7 patients were excluded on the basis of information recorded 
before the randomization. To reduce drop-outs one reminder was sent to those who did not 
answer the questionnaires. Additionally, participants chose between answering the 
questionnaires on paper or electronic. Two methods of collecting questionnaires could cause 
the questions to be interpreted differently by respondents. However, a recent review and 
meta-analysis concluded that paper and electronic administration of patients related 
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outcome measures are quantitatively comparable [124]. The majority of participants in our 
trial answered the questionnaires via the Internet, and relatively few were lost to follow up 
at 3 and 12 months (Figure 6). We found no statistical differences between patients who 
were included and those who were excluded regarding gender and age (Paper I). Apart from 
3.5 years older respondents as compared to non-respondents at 12 months (P = 0.020), we 
found no differences in the dropout analyses at 3 and 12 months (Paper III). To avoid further 
issues with attrition we also analyzed the 3 and 12-month material with intention-to-treat.    
 
Two neurologists (the first and last author of all four papers) performed all consultations, 
and took part in both data collection and analyzing the data, which could have complicated 
the study outcomes. To increase the internal consistency of the study, the first author was 
primarily responsible for data collection and analysis, but methods and findings were 
discussed and consulted with the two other authors. Detection bias is often handled by 
blinding personnel and/or patients. Because the two studied consultation types are quite 
different, blinding would require more resources and make the logistics more complicated 
by adding another researcher.   
 
By sending the questionnaires three and 12 months after the consultation, we wanted to 
ensure enough time for reflection, but simultaneously not wait too long and risk too much 
recall bias. Nevertheless, recall bias is a limitation of the study, especially the results from 
the 12-month questionnaire. To reduce this at consultation, the waiting time was set to not 
more than 4 months from the date of the referral letter. In paper IV, we compensated for 
the recall bias by thoroughly rereading every participants electronic patient record in 
Northern Norway. 
 
To avoid effects on causality, confounders have to be identified and conditioned on in the 
analysis (if possible). By having the telemedicine and the traditional consultation at the same 
hospital, we ruled out the confounding effects of travel, the use of different personnel and 
the use of different locational settings prior to randomization. Additionally, all included 
patients were referred from primary care in Northern Norway, and their age was limited to 
that of a working population. In this way, patient conditions were similar to the point of 
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randomization, and the inclusion criteria was identical as well. Other confounding effects in 
this trial were ruled out by the concealed randomization.  
 
We reduced plausible confounders, used a strict and structured protocol, and compensated 
for bias by concealed randomization. This made it relatively easy to interpret differences 
between telemedicine and traditional consultations. Hence, this trial has a high internal 
validity for the comparisons of the two randomized groups. However, just being part of a 
















6.3 Random error  
Every significant finding can occur by chance (random error). In superiority trials, a type 1 
error (α) means reporting a false outcome difference by erroneously rejecting the null 
hypothesis (H0). The analyses of the primary hypothesis may be robust, but the chance to 
get a false-positive result is increased in the secondary analysis due to multiple testing, 
especially in the non-prespecified and post hoc hypothesis. This is especially a limitation of 
the significant results claiming telemedicine superiority in paper 2. A type 2 error (β) would 
be failure to reject the H0 when there is a true difference in outcome.  
 
In contrast to a superiority trial, the null hypothesis (H0) in a non-inferiority trial states that a 
treatment is inferior to a control: 
H0: Share of satisfied patients with a telemedicine consultation is inferior to that of a 
traditional visit by ≥ 15% 
H1: Share of satisfied patients with a telemedicine consultation is non-inferior to a traditional 
visit by a margin of < 15% 
Thus, the definitions of type 1 and 2 errors are in fact reversed as compared to a superiority 
trial.  
 
A type 1 error would be to claim that telemedicine is non-inferior by a prespecified margin 
to a traditional visit, when it is truly inferior (erroneously rejecting H0). Intention-to-treat 
analysis may increase the risk of type 1 error in non-inferiority trials. In our trial, we saw that 
missing answers in the questionnaire “diluted” the share of satisfied patients (Paper II and 
III), and drew the conclusion towards rejecting H0, or even claiming superiority in some 
satisfaction variables (Paper III). Conversely, intention-to-treat analysis preserves the value 
of randomization, and mirrors reality [125]. In our trial, the per-protocol and the intention-
to-treat analysis coincided in that both concluded non-inferiority of telemedicine (Paper II – 
IV).  
 
A type 2 error would be failure to reject the H0 hypothesis when telemedicine consultations 
are truly non-inferior by a prespecified margin. This type of error can be caused by a too 
small sample size, a too short follow-up period or flawed design. To avoid type 2 errors, we 
made a prespecified power analysis for the primary satisfaction variable(s), and ensured 
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enough included patients. Additionally, patients were followed up by questionnaires at 3 
and 12 months, and to ensure a dynamic long-term evaluation, we combined the satisfaction 
variables at 3 and 12 months (Paper III). We did not calculate statistical power of other 
variables, but in our analysis, we did not conclude that telemedicine consultations are 
inferior to traditional consultations. Thus the risk of making a type 2 error was removed in 
the primary analysis, but would still be possible in the subgroup analysis.  
 
6.4 External validity  
During the trial period, we mirrored daily life in our Department of Neurology by 
consecutively recruiting and consulting 72.2% of all the referred nonacute headache 
patients. The study participants did not significantly differ in age and gender to the 27.8% 
who did not participate. Moreover, patients in our trial are similar in characteristics to those 
with primary headaches referred to other secondary neurologic departments and headache 
clinics: a high proportion of women and migraineurs, in fertile age, and with a high headache 
burden [57, 126]. To the extent possible, we also followed and reported study findings 
according to the CHEERS and CONsolidated Standards Of Reporting Trials (CONSORT) 
statements [80, 117, 120]. For these reasons, generalizability is a strength of this trial. The 
fact that our trial was retrospectively registered in a World Health Organization (WHO) 
registry (before inclusion of the first patient) could make it more prone to reporting and 
publishing bias [122]. However, the trial was registered in time at the Norwegian Research 
and Management database. In order to improve the research transparency, and prevent 
distortion of the scientific evidence, we labelled prespecified and non-prespecified 
outcomes in the papers [122].  
 
A limitation is that we did not include patients older than 65 and younger than 16 years of 
age, neither did we include patients with suspected secondary headaches (except MOH). 
The results in this trial can thus not be generalized to patients beyond this age range, and 
not to patients with suspected secondary headache other than MOH. 
Since the headache patient and neurologist were in the same location (but different rooms), 
the trial provides a proof of concept (as for a feasibility study), but is not equivalent to a 
consultation where patients are going to a satellite clinic (presumably closer to their home) 
and being connected to a remote neurologist (presumably located at a major neurologic 
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center). Our design obviously increases the internal validity at the expense of the external 
validity of the study. On the other hand, the remote technology has gained momentum, and 
the technology needed for a remote consultation, with similar qualities as those we did in 
hospital 2-3 years ago, is available in most households in Europe [127]. Additionally, 
telemedicine does not depend on distance; the neurologist is not physically present in the 
consultation room.  
 
The rural areas, which are expected to benefit the most from telemedicine, are sparsely 
populated. To enroll enough patients in a “real life” study, we would need multiple 
telemedicine satellite locations spread out over these rural areas (Figure 2). Such a study 
would be very challenging. It would be extremely expensive, and very problematic to both 
educate and maintain appropriate scientific personnel in all areas. Prior to this trial, the 
researchers actually made an attempt in a rural hospital in Mosjøen (see Preface) with an 
area of coverage of approximately 70 000, but failed to enroll enough patients and to 
maintain the scientific personnel necessary to continue this design. Based on these 
limitations, our study design, though a bit artificial, was the closest we could get to study 

















7. GENERAL DISCUSSION 
In this thesis, I present an alternative paradigm in the management of nonacute headache 
patients. In paper I, we assessed nonacute headache patients’ acceptability of telemedicine, 
estimated time and cost savings and evaluated the feasibility of telemedicine by comparing 
it to the traditional in-person face-to-face consultation. In paper II and III, we assessed 
patients’ satisfaction of telemedicine. Treatment efficacy of telemedicine was presented and 
compared to traditional consultations in paper I, II and IV. Finally, safety of telemedicine 
consultations was discussed in paper IV. Here, I further discuss acceptability, satisfaction, 
management, efficacy, cost, feasibility and safety of telemedicine consultations for nonacute 
headache disorders. It is complicated to perform a neurologic examination via telemedicine. 
Therefore, a part of this discussion is about the role of neuroimaging and examination of 
headache patients. In the last part of this discussion telemedicine dynamics, perspectives 
and implementation will be discussed.     
  
7.1 Acceptability and satisfaction  
An essential requirement in order to implement telemedicine successfully, is a patient 
centered view. Patients have to accept the consultation type, and be satisfied with the 
technology. We found a high share of telemedicine acceptance among nonacute headache 
patients. Although almost all who underwent the telemedicine visit in our study were 
satisfied with the video- and audio quality, a direct interview may cause bias due to patients 
being polite. However, high rate of acceptance is supported by findings in other 
telemedicine studies [128]. Conversely, previous surveys, including a survey from our own 
region, report low levels of satisfaction among headache patients [15, 107]. The huge and 
far-flung area of coverage with lack of headache specialists in most of the rural areas that we 
serve (Figure 2), brings challenges in providing proper specialist care for headache patients 
[15, 35], thus being an indirect cause of the previously reported high share of unsatisfied 
patients. Longer waiting time for patients in the rural areas (Table 4 in paper I), corresponds 
to the problematic travel logistics to get appropriate headache care.  
 
According to Statistics Norway as of 1. October 2015, almost all of the Norwegian 
households have internet access, and 91% have a broadband internet connection at home 
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[129]. This corresponds with Eurostat data from 2016, which states that 85% of European 
households have access to the internet, and 83% have broadband connection [127]. 
Additionally, about half of the population in Europe, and 60% in the US, with internet 
connection use the internet for health related purposes [130]. According to these data, it is 
not about the access to high quality hardware and software, it is about the lack of access to 
specialist headache care [15]. Headache patients recognize the need for proper access and 
availability of headache specialists. This is reflected in the high proportion of telemedicine 
acceptance and satisfaction in our trial.  
 
A weakness is that we failed to compare questions about satisfaction up against a 
standardized questionnaire or rating scale. On the other hand, similar satisfaction questions 
and aspects have been used by others [15, 107, 108, 131]. Although it is guaranteed that we 
did not cover all aspects of satisfaction in this trial, the other studies show that the questions 
we asked (Paper I, II and III) bring light to many of them (Table 6) [132]. High Cronbach’s 
alpha shows that the satisfaction questionnaire at 12 months is reliable (Paper III). The high 
level of satisfied patients corresponds well to satisfaction reported on telehealth delivered 
to other pain conditions [133-135], as well as to other neurologic and medical conditions 
[108, 136].  
 
7.2 Efficacy  
The treatment efficacy outcomes were primarily evaluated by the use of the headache 
specific patient related outcome measure HIT-6 and by the visual analogue pain scale (VAS). 
The HIT-6 is both reliable and valid across different headache conditions, and considered as 
a main headache outcome measure [98, 137, 138]. It has been translated into 28 languages, 
and both the cultural and linguistic content were considered comparable in all the three 
Scandinavian languages [139]. Cronbach’s alpha at baseline, 3 and 12 months correspond to 
high level of internal HIT-6 consistency. Specific patient related outcome measures, such as 
HIT-6, have the advantage that they are more target focused, thus get more relevance and 
become more responsive to the research question(s). The drawbacks are that they are not 
as extensive on health-aspects as the generic patient related outcome measures, and have 
limited potential to assess unexpected effects of treatments. In this trial, however, we had 
many variables that considered headache, general health and social aspects as well. VAS has 
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been found valid and reliable across different pain conditions as well as headache, and is 
further discussed in paper I [100, 101].     
 
Although we found no differences in headache specific endpoints between the randomized 
groups (Paper II, III and IV), at 3 months more patients from rural areas visited their general 
practitioner in the traditional group (Table 5 in paper II). However, there was no difference 
in the 12-month material (unpublished data), and the 3-month significant findings could be 
caused by chance.  
 
Nevertheless, it is conceivable that the decline in HIT-6 and probably VAS in our trial may be 
explained by a deviation to the mean, especially since a primary care cohort found similar 
changes in HIT-6 at 10 months follow-up [140]. Due to the long and tiresome travel 
conditions in our area of coverage, those who were referred in the first place were probably 
the most heavily afflicted and the most difficult to treat, and patients’ symptoms may 
decline over time with or without treatment. It might be argued that non-inferiority of 
telemedicine compared to traditional consultations has been demonstrated. However, the 
efficacy of either treatment to usual care has not been demonstrated. Notably, however, 
about half of the consulted patients had a decrease in the HIT-6 and VAS scores beyond that 
of a minimal clinical improvement (Table 3 in Paper III) [99, 101].  
 
7.3 Cost evaluation  
After getting similar treatment and safety outcomes in the telemedicine and traditional 
groups, telemedicine moves towards quadrant 2 in the cost effectiveness plane (Figure 5). 
Based on quadrant 2, it is considered as unnecessary to calculate an ICER. Although we did 
not make a study on cost-effectiveness, the treatment and safety results at 12 months 
strengthen the cost analyses in paper I. In a cost minimization perspective, these results 
strongly indicate cost-effectiveness of telemedicine. In fact, we found that telemedicine 
visits were about 5 minutes shorter than traditional visits (Table 2 in paper I), which may add 
to its cost effectiveness. Moreover, since the regional health authority covers most of the 





Few studies that explore structural changes or secondary causes of nonacute headaches give 
explicit information about the content of the neurologic examination that was performed 
[57]. PubMed searches on this topic 4.5.2017 did not reveal studies showing economic 
benefits of not performing a neurologic examination. However, a full neurologic examination 
is time consuming.  
 
7.4 Feasibility and safety  
Although we controlled for travel and location confounders, there was a high share of 
patient acceptance, a high proportion of both short and long-term satisfied patients and 
indifference to consultation type (Paper I, II and III). These findings add strength to the 
feasibility evaluation.  
 
We only encountered minor technical problems, and most patients were satisfied with the 
quality of the telemedicine consultation (Table 2 in paper I). In consultation related 
outcomes, we found no differences favoring traditional visits, and the consultation time was 
actually in favor of telemedicine (Table 2 in paper I). The facts, that the follow-up 
questionnaires revealed no differences in headache related outcomes between the two 
randomized groups (Paper II, III and IV), that there was less follow-up in patients who 
underwent telemedicine (Paper II), and that no statistical difference in safety aspects after a 
thorough review of all participants electronic hospital records (Paper IV) was found, bring 
more credibility to telemedicine feasibility in the treatment of nonacute headaches. 
Although new issues come with new technology, these findings could lead towards a more 
beneficial and patient centered headache care in the future. 
 
The major advantage of an in-person consultation is the direct physical interaction between 
the doctor and the patient, and the possibility to do a full physical and neurologic 
examination. A traditional view is that the examination brings reassurance, and strengthens 
the bond between the doctor and patient [141]. However, most patients would probably not 
like to be examined just for the sake of being reassured. Despite not being examined, 9 out 
of 10 patients were satisfied with the consultation in this trial. The physical presence tends 
to be provider centered, and thereby resulting in less power balance between the doctor 
and the patient [76]. A limitation of the traditional visits could be the lack of the 
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psychological and physical virtual space present in telemedicine [76]. However, this space 
could also be a barrier to proper care.    
 
Why is it necessary to do a neurologic examination in a patient with nonacute headache? 
The main reason is to diagnose secondary causes to avoid unanticipated consequences of 
misdiagnosis and mistreatment. Therefore, examining a patient or not should primarily be 
based on medical reasoning. The amount of examination ought to be disease and situation 
specific. Physicians usually identify headache phenotypes and warning signs (Table 5) by a 
structured interview [57], and the neurologic examination has become less important due to 
the availability of neuroimaging [142]. In the trial, we only included patients with either a 
normal neurologic examination reported by the referring doctor, or no signs of pathology 
suggestive of a secondary headache cause on neuroimaging (Paper I) [25]. Thus, we 
acknowledge the uncertainty associated with quality of the clinical examinations reported in 
the referrals. Nevertheless, our data at one year revealed only one secondary headache in 
each of the randomized groups, suggesting that not performing a neurologic examination 
after these given criteria is safe. Support to this view is also found in neuroimaging studies 
[49-57]. 
 
7.5 Neuroimaging and examination  
The US headache consortium made a meta-analysis of 1086 patients with migraine 
headache and normal neurologic examination in 2000 [92]. They found the frequency of 
intracranial pathology on neuroimaging to be 0.18%. Consequently, the consortium 
concluded that patients with a typical migraine and a normal neurologic examination are 
unlikely to have pathology on neuroimaging. However, a major weakness was that most of 
the studies they included did not inform about aspects of the neurologic examination. 
Furthermore, more than 2/3 of the patients were from studies made in the 70ties and 
80ties, using low quality CT scans. Additionally, the meta-analysis comprised both CT and 
MRI studies, and did not differentiate between them. Neither did we differentiate between 
CT and MRI scan results. 
 
In 2004, Sempere et al screened 1876 patients with nonacute headaches [57]. All underwent 
a “tailored” neurologic examination depending on patients’ complaints [57]. Of these 1861 
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(99.2%) had a normal examination, 1432 underwent a CT, 580 an MRI and 136 both. 
Significant intracranial pathology was found in 1.17% (22/1876) [57]. Seventeen of the 1861 
patients (0.91%) with normal examination had significant abnormalities on neuroimaging, 
and nine of these had either migraine or tension-type headache [57]. The five patients with 
findings on neurologic examination and neuroimaging had indeterminate headaches that 
would warrant a head scan anyway [57].  
 
Sempere and colleagues found three patients with papilledema and normal neuroimaging; 
all were diagnosed with idiopathic intracranial hypertension [57]. Accordingly, findings of 
significant pathology on neurologic examination that lead to detection of a secondary 
headache cause was 0.16% (3/1876). Despite different methodology, this finding is 
comparable to our trial, in which a second opinion neuroradiologic investigation revealed 
signs of idiopathic intracranial hypertension in one patient.  
 
Thomas and collaborators report brain CT scans of 215 nonacute headache patients from 
general practices in Scotland [53]. Three of the patients (1.4%) had significant structural 
findings related to their nonacute headaches; metastasis from lung cancer, a meningioma 
and an arteriovenous malformation [53]. These findings are also comparable to the finding 
in our trial. In contrast, a study from Africa reports significant pathology on almost half of 
the brain CT scans in patients with nonacute headaches [143].  
 
By performing bibliographical searches on MEDLINE from 1966 until November 2005, Detsky 
and collaborators identified 11 neuroimaging studies of 3725 patients with headaches [58]. 
They concluded that abnormal findings on neurologic examination increase the likelihood 
ratio of intracranial pathology 5.3 times [58]. However, these patients had both acute and 
nonacute headaches. More than 85% underwent a CT scan, there was a long study span, and 
only one study informs about the content of the neurologic examination [58].  
 
On one hand, in some studies significant pathology on neuroimaging in nonacute headaches 
does not exceed findings in a normal population [56, 92, 144, 145]. On the other hand, the 
share of significant pathological findings in the normal population is less than the share 
found in headache participants in a Norwegian population based study [49], as well as in our 
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trial. A meta-analysis of 19559 MRI scans from presumed healthy individuals found 
neoplastic lesions in 0.7% (72 meningiomas, 27 pituitary adenomas, 8 low grade gliomas, 5 
acoustic neuromas, 6 lipomas, 3 epidermoid tumors and 14 unspecified tumors) [145]. The 
same meta-analysis found 375 non-neoplastic lesions in 15559 MRI scans of presumed 
healthy individuals [145]. These lesions included 67 aneurysms, 23 cavernomas, 7 
arteriovenous malformations, 13 signs of demyelinations, 101 cysts, 71 Arnold-Chiari type I 
malformations, 15 signs of hydrocephalus, 4 extra-axial collections of cerebrospinal fluid, as 
well as 74 other abnormalities [145]. The prevalence of any of these incidental findings was 
2.7%, but increased to 4.3% in MRI with higher resolution series [145]. Thus, the differences 
in these studies are not only caused by geographical disparity, but the use of different types 
of equipment and methodologies are also important confounding factors. Additionally, 
incidental findings and anatomical variants are commonly present in patients with primary 
headaches [146]. Due to the probability of incidental findings on neuroimaging, ordering 
head scans due to headache should be discussed with the patient in advance, and primarily 
be based on clinical indication (such as the criteria in Table 5). 
 
One reason for performing neuroimaging in nonacute headache is screening for intracranial 
hypertension. In 2006, Bono et al found that 6.9% of 724 migraine patients without 
papilledema had bilateral transverse sinus stenosis, and 2/3 of these were diagnosed with 
idiopathic intracranial hypertension [147]. The same author found bilateral transverse sinus 
stenosis with idiopathic intracranial hypertension in 4.5% of 198 patients with chronic 
tension-type headache without papilledema [148]. De Simone published 44 patients with 
unresponsive chronic migraine, of whom 38 had increased intracranial pressure [149]. In a 
majority of these patients, the headache improved after lumbar puncture [147-149]. More 
studies are warranted to determine the proper clinical context in which lumbar puncture 
should be performed. Another important question is what diagnoses and treatment patients 
with a primary headache phenotype and increased intracranial pressure without 
papilledema should receive.  
 
Even though significant brain MRI findings in migraine and tension-type headaches are rare, 
some literature recommend brain MRI to rule out secondary causes of tension-type 
headaches and chronic migraine [150, 151]. One reason is the last criterion in the ICHD-3 
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diagnosis of primary headaches, “Not better accounted for by another ICHD- 3 diagnosis”. 
This criterion is made to rule out secondary causes, and the most sensitive method of ruling 
out a secondary cause is by brain MRI. Another reason for considering MRI in tension-type 
headache is that featureless headache is the typical brain tumor headache [23]. Then again, 
most brain tumor headaches have additional neurologic symptoms, and tension-type 
headache is the second most common disorder in humans [21, 23, 152]. 
 
Many review articles, as well as the European guidelines, recommend that neuroimaging 
should be performed with MRI technology in nonacute headaches with warning signs (Table 
5) [51, 59, 153-155]. If warning signs are present and the MRI is normal, a neurologic 
examination and/or a control MRI with additional sequences should be considered. MRI is 
superior to CT in diagnosing secondary headache causes, and in addition gives no radiation 
[51, 59, 153, 154].  
 
Conversely, there are many examples of secondary causes of migraine and tension-type 
headaches [23, 147-149, 156-161]. Both Semper, De Simone and Bonos’ studies show that a 
normal neurologic examination cannot rule out intracranial pathology in patients with 
nonacute headaches, but neither can a normal CT or MRI brain scan [57, 147, 148]. In our 
trial, a radiologist overlooked signs of idiopathic intracranial hypertension in one patient 
(Paper IV). Studies confirm that CT brain scans are of low diagnostic value in nonacute 
headache diagnosis [51, 54], but still, the most common reason for requesting CT scans is 
headache [51]. Although a normal MRI brain scan may lead to patients and physicians’ “false 
sense of security”, it is usually more sensitive than a full neurologic examination. When a 
new imaging technique enters our diagnostic repertoire, or when an information and 
communication technology is implemented, it leads to realignment of our other diagnostic 
tools.  
 
Referring patients to neuroimaging is often more driven by reassurance and patient 
expectations than by recommendations from guidelines [52, 142]. Some neurologists even 
refuse to admit nonacute headache patients unless the patient undergoes neuroimaging on 
beforehand [51]. A general problem is that existing guidelines often do not reflect the 
“actual needs” in clinical practices. Patients want reassurance, and doctors do not want legal 
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legislations. In the literature, ordering neuroimaging without clinical cues of a secondary 
headache (Table 5) is often referred to as overuse [162, 163]. An unanswered question is 
whether implementation of specialist telemedicine consultations for nonacute headaches 
would lead to an increase or a more selective use of neuroimaging.  
  
7.6 Telemedicine dynamics 
Despite many positive results of telemedicine applications in studies, few are implemented 
into clinical practice [91, 164]. From 2009 throughout 2013, neurologic telemedicine routine 
visits in Norway comprised only 0.01 – 0.02% of the total [165, 166]. Although planning 
stages for neurologic telemedicine projects are considered important for implementation on 
later stages, reports about such mainly exist for stroke [167].  
 
Developing user-friendly medical information systems is a demanding task. It relies on well-
organized teamwork, with close cooperation between healthcare personnel and designers, 
to become successful [91, 94]. Interdisciplinary communication between diverging branches 
that use specific languages is tough, and often leads to misunderstandings. Still, finding 
common grounds and understandings by teamwork is important to enhance proper 
development of a product [168]. However, the environment, in which information and 
technical systems work, is dynamic and in constant change. The dynamics makes it more 
difficult to design and implement information and communication technology successfully. It 
is impossible to foresee and adapt to all contingencies. This is why developing a system that 
automatically accommodates to these dynamic changes would be considered impossible.  
 
Previous literature suggests to deal with these changes and technological inadequacies by 
different methods of avoidance, i.e. “fitting augmenting and working around” [169]. Due to 
constant dynamic changes in the social- and work environments, there is often a 
requirement for improvement, to make way for better compatibility between software 
systems and clinical practice. Sometimes, these methods can stimulate to a more 
participatory design, and thereby close gaps between interdisciplinary work between users 
and developers. On the other hand, avoiding problems usually do not make room for 
improvement. Similar approaches of avoidance are presented elsewhere. An example is a 
presentation of how it is possible to keep a process of coordination clean and standardized 
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[170]. Coordination is about how things are working together, and the coordination of 
avoidance is made by “demarcating, procrastinating, delegating and accommodating” [170].  
 
7.7 Future perspectives 
Today, the electronic patient record system in Northern Norway has already become an 
important part of a large, complex and heterogeneous informational infrastructure with 
many actors and actants in constant dynamic interactions (developers, users, hardware, 
software, maintenance personnel, etc.). The system has already reached a level of 
irreversibility and gained momentum. It is difficult to make changes in a big and complex 
informational infrastructure, and different aspects locally may lead to a sluggish negotiation 
process. The bigger this informational infrastructure grows, and the easier it is to use, the 
harder it is to see the processes that run inside the black-box. The hidden processes that are 
running behind will only be visible on system failures or system breakdowns [90]. The bigger 
the information and communication technology system with telemedicine and electronic 
patient records, the more actors and actants will be affected upon a system failure [90].  
 
When all hospitals in Northern Norway became interconnected by the same electronic 
patient record, time consuming gathering of information from different electronic patient 
records ceased, and both patient and hospital staff were no longer dependent on site 
locations, but rather on one functioning electronic patient record in DIPS. Additionally, 
electronic patient referrals and electronic prescriptions have replaced the paper-based 
versions. Since Northern Norway has a defined telemedicine population, all the changes that 
were made in the information and communication network, and especially the shared 
electronic patient record, can promote the use of telemedicine technology. In the field of 
neurology, this could lead to reorganization of the specialized healthcare, giving rise to a 
system based more on patients’ needs, possibly reducing access barriers and giving 
headache patients from different areas equal access to neurologic healthcare (Figure 13). 
However, technologies are not considered neutral entities, and all have more or less effect 
on the daily work. Implementing telemedicine might lead to a redistribution of tasks among 
health care personnel [171]. Such a shift can possibly strengthen the specialist headache 




To be in alignment with an informational infrastructure, headache consultations via 
telemedicine should not replace the traditional neurologic visits. Instead, consultations 
through telemedicine should rather be viewed as an alternative for both headache patients 
and possibly patients with other neurologic disorders as well. In our study, some groups 
seemed to benefit more from telemedicine than others (paper I and III). Specialist 
telemedicine consultations could be used as a tool to tailor a more individual treatment 
approach and delineate geographical differences, i.e. geographical differences in access and 
availability. Consequences would be satisfied headache patients, less travel, and saving 
hospital budgets. In contrast, some neurologists are also travelling, often to make extra 
income. Adding new technology that competes with personal economic gains would likely 
meet some resistance, produce anti-programs and hinder alignment.  
 
The possibility of implementing telemedicine consultations for headache patients in a rural 
far-flung geography, especially in areas such as Finnmark and Svalbard, may have several 
benefits: improved access to neurologic care, less geographic disparity, avoidance of travel 
and unnecessary time expense, and even easier recruitment for clinical trials are some 
possibilities [25, 77, 172]. But other barriers are reluctance to adopt new technology in 
clinical practice, expensive technology, liability concerns, and perhaps most importantly the 
difficulties in performing a proper neurologic examination [77, 172].  
 
Another issue is that telemedicine tends to realign and relocate tasks from specialists to 
other healthcare workers, or from healthcare workers to non-healthcare workers (Figure 13) 
[171]. Even in our own project, we observed that the neurologic examinations were 
“transferred” to some of the referring general practitioners. Even if all doctors should be 
able to perform a neurologic examination, an examination by a specialist would possibly be 
more thorough and precise. New technologies, or use of technology in new fields, are not 
always tested thoroughly before implementation. A new medication has to undergo several 
stages of clinical testing in different studies before it is approved for patients, but this does 
not seem to be of much concern regarding implementation of some technologies used in 




What characterizes the telemedicine projects that have been successfully implemented? 
According to a qualitative literature review, implemented telemedicine applications have the 
following features in common: “1) Local service delivery problems have been clearly stated, 
2) telemedicine has been seen as a benefit, 3) telemedicine has been seen as a solution to 
political and medical issues, 4) there was collaboration between promoters and users, 5) 
issues regarding organizational and technological arrangements have been addressed, and 
6) the future operation of the service has been considered” [164]. In this thesis, and in paper 
I-IV, we described how telemedicine potentially can countervail the geographical disparities 
and provide equal specialist headache care regardless of the distance to our Department of 
Neurology. Although this thesis is mainly patient centered, some economic hospital 
perspectives (paper I and thesis) have been covered. The equipment infrastructure is 
incorporated in the Department of Neurology, but in use for other purposes. Finally, the 
local settings (Figure 13) and future perspectives have been considered, but more planning 
and funding remain to be elaborated on. The project, being built from a bottom-up 
approach, provides further optimism for successful implementation [63, 64]. Given the 
conditions in our area of coverage (Figure 2), this project has verified that telemedicine for 
headache patients could be successful in similar rural or remote areas, as well as in other 
areas where access to care is cumbersome. Because most households in our area have high 
speed internet connections, we plan to bypass the satellite locations in smaller rural 
hospitals. In the next headache project, we intend to investigate predictors for successful 
implementation of telemedicine by streaming audio- and video from a specialist center 







                                                                                                                                                                 
Figure 13 Key actors and actants in a future perspective of the neurologic situation in 
Northern Norway. A shared Electronic Patient Record (EPR) has already “replaced” all the 
local patient records. Implementation of telemedicine will probably lead to increased power 
and importance of the neurologic base in Tromsø, increased power and importance of the 
Information Technology (IT) help, and less travelling by headache patients, neurologists and 
other health care personnel. In general, such a change may additionally lead to realignment 
of neurologic patient follow-up, i.e. implementation of telemedicine may lead to less travel 















8. CONCLUSIONS  
This thesis shows that a telemedicine consultation is a good alternative to a traditional 
specialist headache consultation. It documents that most patients with nonacute headaches 
accept telemedicine, and that these patients are not less satisfied with telemedicine 
compared to a traditional in-person consultation. Although the trial is not a cost-effectivity 
study per se, it strongly suggests that telemedicine is cost-effective, and that the 
consultations are feasible. When selecting patients by given criteria, telemedicine is safe, 
and non-inferior to the traditional visit. Additionally, this study provides evidence that 
consulting patients with nonacute headaches without performing clinical neurologic 
examination is safe.  
 
I suggest increased implementation of this consultation type in many neurologic 
departments, to increase access to specialist and offer better and more convenient follow-
up [11, 12, 14, 35]. The trial, which this thesis is built on, is a good foundation for 
establishing telemedicine as a supplement for patients with nonacute headaches in the 
region of Tromsø University hospital, but probably also for many other health regions 
around the world. Therefore, our next step will be to implement telemedicine into clinical 
practice, with direct audio- and video communication from the Department of Neurology in 
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VAS, P = 0.49 not 0.82 
HIT-6, P = 0.82, not 0.49 
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1. Søknader på pasienter med hodepine ”plukkes opp” fra søknadsbunken. Disse 
identifiseres via funksjonen ”eksterne søknader” som installeres via ”Help-desk”. 
Pasienter som ikke fyller kriteriene overføres til ekspedisjonen for vanlig timeoppsett 
(”nevrologiske henvisninger”), mens pasienter som oppfyller kriteriene overføres til 
KM, SIB eller CW for behandling.  
2. Hvis kriteriene er oppfylt, sendes informasjonsbrev til pasienten. Deretter tas det 
kontakt med pasienten telefonisk for å sjekke om de aksepterer telemedisin og er 
interessert. Hvis pasienten samtykker (muntlig), oversendes samtykkeskjema, 
spørreskjema og innkallingsbrev til pasienten, og pasienten inkluderes i prosjektet.  
- Hvis pasienten ikke gir samtykke sendes henvisningen tilbake til ansvarlig nevrolog 
som vurderer søknaden på vanlig måte.  
3. Randomiseringskontoret kontaktes for å få randomisert nummer – telemedisin eller 
vanlig konsultasjon. Randomiseringstelefon: 776 69117 (Ingrid Sandstad). 
Åpningstider: Mellom kl. 0800-1530. Pasientene informeres om dette etter at de har 
kommet til sykehuset. Selve randomiseringen kan foretas i forkant (det avtales med 
randomiseringskontoret hvor lang tid man kan akseptere + prosedyre for å 
randomisere per lege, dvs. at det er tilfeldig hvilken lege som undersøker)  
4. Pasienten informerers om prosjektet etter at de har møtt opp og det taes blodtrykk, 
høyde og vekt (dette gjøres på dagenheten). Spørreskjemaet gjennomgåes for å 
kontrollere at det er utfylt riktig. Sykepleier følger pasienten til konsultasjonen. 
5. Nevrolog utfører enten telemedisinsk eller vanlig konsultasjon etter protokoll. 
Konsultasjonen avsluttes på vanlig måte, og ansvarlig nevrolog gjør 
registreringsarbeidet i DIPS (avslutter eller setter opp til ny time) 
6. Anna Kirsti oppdaterer administrativ protokoll og følger opp med utsendelse og 
innhenting av spørreskjema etter 3 og 12 mnd. 
7. Administrator sender spørreskjema med frankert svarkonvolutt/Questback til 
pasientene etter 3 mnd og 12 mnd. og fyller ut administrativ protokoll. Det er viktig 
at tidsfristene overholdes. Purring hvis pasienten ikke svarer innen 2 uker.  










Data from referral letters 
 
 
Telemedisinsk konsultasjon for 
hodepine  
 
En randomisert studie blant hodepinepasienter henvist 
fra fastlege til nevrolog  
       
                                           





1. Registrere informasjon fra henvisningen (nevrolog) 
2. Telefonintervju (prosjektkoordinator)  
a. Informasjon om prosjektet 
b. Avklare inklusjonskriterier og akseptans av telemedisin,  
(dvs. om pasienten egner seg for å være med) 
c. Registrere telefonnummer og e-post adresse 
3. Spørreskjema (Fylles ut ved oppmøte før konsultasjon) 
4. Konsultasjon hos nevrolog  
5. Tre-måneders oppfølging (Student) 
a. Sende ut spørreskjema 
b. Evt. purre 
6. Tolv-måneders oppfølging (Student) 
a. Sende ut spørreskjema 
b. Evt. purre 
 
Pasient randomiseringsnummer: (0 til 400, første pasient starter på nr. 22) 
Kjønn: 1. mann 2. kvinne 
Alder:  
 
1. Opplysninger hentet fra henvisningen 
 
1a. Årsak til henvisning (sett ett kryss) 
____ Avklare diagnosen   
____ Behandling av hodepinen   
____ Henvisningsårsaken fremgår ikke av søknaden   
____ Annet, beskriv__________________________________________________ 
 
1b. Diagnose fra henvisningen 
____ Migrene   
____ Tensjonshodepine   
____ Migrene+tensjonshodepine 
____ Cluster 
____ Hodepine (uspesifisert)   
____ Fremgår ikke 
____    Annen diagnose 
 
2. Hvem henviste? (sett ett kryss) 
____ Fastlegen   
____ Vikarlege   
____ Turnuslege   
____ Andre, beskriv____________ 
 
3. Avklaring av inklusjonskriterier så langt som mulig basert på henvisningen (kryss av) 
____ Alder 16-65 år 
____ Ikke vært hos nevrolog de siste 2 år pga. hodepine  
____ Ingen kjent sykdom som kan forklare hodepinen  
____ Ventetid under 4 måneder 
____ Behersker norsk språk 
 
 
4. Påvirker hodepinen utførelsen av daglige aktiviteter? (sett ett eller flere kryss kryss) 
____ Nei   
____ Ja, sykmeldt / arbeidsufør   
____ Ja, hodepinen begrenser utførelsen av daglige aktiviteter  
____ Ikke angitt i henvisningen 
 
5. Foreligger det opplysninger om utredning og behandling i søknaden? (sett ett eller flere 
kryss) 
____ Nei   
____ Ja, smertestillende medikamenter, 
hvilke(n)_____________________________________ 
____   Ja, andre medikamenter mot hodepine, hvilke(n) 
_________________________________ 
____ Ja, migrenemedisiner, hvilke(n) 
_______________________________________________ 
____ Ja, blodtrykksmedisin mot hodepine 
____ Ja, epilepsimedisin eller andre medisiner mot hodepine 
____ Andre medikamenter 
____ Medikamentbruk ikke angitt i henvisningen  
____ Fysioterapi 
____ Andre behandlingsformer 
____    MR undersøkelse 











Participants’ pre-filled questionnaire 
 
 
Deltaker nr _________  
 
 
Telemedisinsk konsultasjon for hodepine 
 
En randomisert studie blant hodepinepasienter henvist fra 












Spørreskjemaet fylles ut og tas med til undersøkelsen ved  
Nevrologisk avdeling, UNN 
  
 
3. Spørreskjema (blodtrykk måles av forskningsmedarbeider, 
resten gjør pasienten selv) 
 
6. Personlige data 
 
____ Mann 
____ Kvinne  
____ Gift/samboer 
____ Enslig  
 
Høyde: ……cm  
Vekt:………kg  
Blodtrykk: ..…/……   
 
7. Hva var hovedhensikten med å bli henvist til nevrolog. Sett ett eller flere kryss 
____ Diagnostisk avklaring (usikker diagnose)  
____ Manglende effekt av behandling for hodepine  
____ Mistanke om annen sykdom som årsak til hodepinen  
____ Kronisk hodepine  
____ Forsikring for pasienten eller pårørende  
 
8. Har du tidligere vært undersøkt av nevrolog p.g.a. hodepine?   
____ Nei  
____ Ja, når (år) _____ 
 
9. Har du noen gang vært innlagt på sykehus p.g.a. hodepine?  
____ Nei  
____ Ja, når (årstall) _____ 
 
10. Hvem foreslo å henvise deg til nevrolog for hodepine? (sett ett kryss) 
⁭  Fastlegen 
⁭  Andre leger (hvem)________________ 
⁭  Andre helsepersoner (hvem)_________________ 
⁭  Pasienten selv 
⁭  Pårørende 
⁭  Andre (hvem)______________________ 
 
11. Hva er din høyeste fullførte utdanning? (ett kryss) 
____ Grunnskole eller folkehøyskole 
____ Yrkesfaglig videregående, yrkesskole eller realskole 
____ Allmennfaglig videregående skole eller gymnas 
____ Høyskole eller universitet, mindre enn 4 år 
____ Høyskole eller universitetet, 4 år eller mer 
 
12. Hvor mange års skolegang har du? (ta med folke- og ungdomsskole)  
____ år 
 
13a. Hva er din hovedaktivitet? (sett ett kryss) 
____ Yrkesaktiv heltid. Angi yrke: ____________________________________  
  
____ Militærtjeneste 
____ Yrkesaktiv deltid    
____ Arbeidsledig 
____ Hjemmeværende 
____ Pensjonist/trygdet    
____ Student  
____ Fødselspermisjon 




13b. Har du skiftarbeid? 
____ Ja 
____ Nei   
 
14. Mottar du noen av følgende ytelser? 
____ Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon 
____ Sykepenger (er sykmeldt) 
____ Rehabiliterings-/attføringspenger 
____ Uføreytelse/pensjon, hel 
____ Uføreytelse/pensjon, delvis 
____ Dagpenger eller arbeidsledighet 
____ Overgangsstønad 
____ Sosialhjelp/-stønad 
____ Annet, beskriv _________________________ 
 
15. Hvis du er sykmeldt; hva er årsaken til det? 
____ Hodepine 
____ Annet, beskriv ______________________ 
 
15b. Hvor lenge har du vært sykmeldt? 
____ Uker  
 
16. Familiær situasjon / hodepine i familien 
____ Gift, samboer 
____ Enslig 
____ Annet, beskriv _____________________ 
____ Nærmeste slektninger (foreldre, barn) har lignende hodepine som meg 
____ Andre slektninger (besteforeldre, tanter, onkler, søskenbarn etc) har lignende 
hodepine som meg (sett strek under) 
 
17.Hvor ofte driver du mosjon? (med mosjon mener vi at du for eksempel går en tur, går på 
ski, svømmer eller driver trening/idrett) 
____ Aldri 
____ Sjeldnere enn en gang i uken 
____ En gang i uken 
____ 2-3 ganger per uke 
____ Omtrent hver dag 
 
18. Hvor hardt mosjonerer du da i gjennomsnitt? 
____ Tar det rolig uten å bli andpusten eller svett 
____ Tar det så hardt at jeg blir andpusten og svett 
____ Tar meg neste helt ut 
____ Mosjonerer ikke 
 
19. Hvor lenge holder du på hver gang i gjennomsnitt? 
____ Mindre enn 15 minutter 
____ 15-29 minutter 
____ 30 minutter – 1 time 
____ Mer enn 1 time 
 
20. Bruker du medikamenter eller andre preparater? 
____ Smertestillende  
____ P-piller  
____ Annen medisin, hvilken _____________________ 
____ Ingen medisiner (reseptbelagte og/eller reseptfrie) 
____ Kosttilskudd, hvilke(n) _____________________ 
____ Naturpreparater, hvilke(n) ___________________ 
____ Andre ”alternative preparater”, hvilke(n) _________________________ 
____ Annen alternativ behandling, hvilken(n) __________________________ 
 
21. Hvor ofte bruker du smertestillende medisiner? Sett ett kryss 
____ Hver dag 
____ Minst 3 dager per uke  
____ 1-2 dager per uke  
____ Mindre enn 1 dag per uke, men minst annenhver uke  
____ Sjeldnere enn hver annen uke 
____ Minst 14 dager per måned 
 
22. Hvis du bruker smertestillende, oppgi navn på medisinen(e): 
___________________________ 
 
23. Bruker du migrenemedikamenter? 
____ Ingen  
____ Imigran/Zomig/Naramig/Maxalt/Relpax/Almogran (sett strek under) 
 
24. Hvor ofte bruker du migrenemedisiner? 
____ Hver dag 
____ Minst 3 dager per uke  
____ 1-2 dager per uke  
____ Mindre enn 1 dag per uke, men minst annenhver uke  
____ Sjeldnere enn hver annen uke  
____Minst 14 dager per måned 
 
25. Hvis annen medisin, skriv navn på medikamentet 
____________________________________ 
 
25a. Hvor ofte drikker du alkohol? 
____ Aldri 
____ Månedlig eller sjeldnere 
____ 2-4 ganger hver måned 
____ 2-3 ganger pr. uke 
____ 4 eller flere ganger pr. uke 
 






____ 10 eller flere 
 
25c. Har du røykt / røyker du daglig? 
____ Ja, nå 
____ Ja, tidligere 
____ Aldri 
 
26. VAS (smerteskala der du skal angi grad av smerte) 
Vi ber deg angi graden (intensiteten) av hodepine fra svært lite til svært mye. Skalaen går fra 1-10 der 
1 er lite intens hodepine, mens 10 er svært intens hodepine. 
 




Spørre skjema om innvirkningen av hodepine på livet ditt. Dette spørreskjemaet er blitt utformet for 
å hjelpe deg med å beskrive og gi uttrykk for hvordan du har det, og hva du ikke kan gjøre pga. 
hodepine.  
Vennligst kryss av i passende rute for hvert spørsmål: 
1. Når du har hodepine, hvor ofte er smertene sterke? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
2. Hvor ofte begrenser hodepinen deg til å utføre vanlige daglige gjøremål slik som husarbeid, arbeid, 
skolearbeid eller å ha sosial omgang? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
3. Når du har hodepine, hvor ofte ønsker du at du kunne legge deg ned? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
4. I de siste 4 ukene, hvor ofte har du følt deg for trett til å utføre arbeid eller daglige gjøremål på 
grunn av hodepine? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
5. I de siste 4 ukene, hvor ofte har du følt deg lut lei eller irritert på grunn av hodepine? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
6. I de siste 4 ukene, hvor ofte har hodepinen begrenset din evne til å konsentrere deg om arbeid 
eller daglige gjøremål? 
 










Structured interview (The consultation)  
 
 
4. Konsultasjon hos nevrolog 
 
28. Undersøker: ______   
 
29. US dato: __________  
 
30. Ventetid (dager) ______  
 
31. Tidspunkt for start av konsultasjon: Time ______ Min ______ 
 
32. Spørreskjemaet som pasienten har fylt er sjekket og funnet i orden 
___ Ja 
 
33. VAS på konsultasjonstidspunktet: _____  
 
34. HIT-6 på konsultasjonstidspunktet: _____ 
 
35. Randomisert til: 
____ Telemedisin  
____ Ordinær konsultasjon  
 
36. Spørsmål som stilles alle pasientene (som hjelp til å klassifisere hodepinen). Gjelder den mest 
fremtredende hodepinen (hvis pasienten har flere hodepiner) + nevrologens vurderinger 
1. Er hodepinen ____ konstant eller ____ anfallsvis?  _____ begge deler 
2. Er hodepinen ____ ensidig eller ____ dobbeltsidig eller ____ begge deler 
3. Er hodepine ____ pressende / klemmende _____ pulserende  ____ stikkende 
4. Hvor lenge varer hodepinen? ____ timer eller dager (stryk det som ikke passer) 
5. Hvor hyppig kommer hodepinen? ____ antall ganger om dagen, uka, måneden (stryk) 
6. Har pasienten tilleggssymptomer? Hvilke(n) ________________________________ 
7. Er hodepinen ____ mild, ____ moderat eller ____ sterk? (kryss av) 
8. Forekommer det ____ en eller ____ flere typer hodepine? (kryss av). Antall: _____ 
9. Utløsende faktorer? Hvilke(n) ___________________________________________ 
10. Er det forvarselsymptomer før hodepinen ____ Nei     ____ Ja, hvilke(n)__________ 
11. Fysisk aktivitet fører til 1. forverring, 2. bedring 3. ingen innvirkning 
12. Hodepinen er relatert til menstruasjon 1. Ja      2. Nei 
 
37. Spørsmål som stilles alle pasientene (for å kartlegge sekundær hodepine) 
1. Ny eller annerledes hodepine 
2. ”Thunderclap” hodepine (max intensitet innen sekunder til minutter) 
3. Alvorligste hodepine noen gang 
4. Ledsagende fokale nevrologiske symptomer 
5. Endring av eksisterende hodepine 
6. Nyoppstått hodepine etter 50 år 
7. Hodepine assosiert med systemiske symptomer (feber, vekttap etc) 
 
 
38. Antall hodepinedager siste måned:  
____ over 15 dager  
____ 7-15 dager  
____ under 7 dager 
 
39. Hvis varigheten av hodepinen er < 4 døgn (dvs. dersom migrene eller annen anfallsvis hodepine 
forekommer): Hvor mange ”anfall” per måned (gjennomsnitt siste 3 måneder): 
 ____ anfall  
 
40. Ved daglig hodepine: Hvor mange ”anfall” per dag (gjennomsnitt siste 3 måneder)? 
____ anfall 
 
41. Har symptomene endret seg i ventetiden? (sett ett eller flere kryss) 
____ Ja, bedre 
____ Antall hodepinedager har avtatt 
____ Hodepinen har blitt mindre intens 
____ Annet, beskriv __________________________ 
____ Nei, uforandret 
____ Nei, verre 
____ Antall hodepinedager har økt 
____ Hodepinen har blitt mer intens 
____ Annet,  beskriv _____________________________ 
 
42. Bortsett fra hodepine, hvilke andre sykdommer har du eller har du hatt (sett strek under) 
____ Frisk  
____ Høyt blodtrykk  
____ Andre nevrologiske sykdommer, beskriv ______________ 
____ Andre systemiske, ikke-nevrologiske sykdommer ____________________________ 
 
43. Har du i løpet av det siste året hatt smerter eller stivhet i nakke- og/eller skulder muskulaturen 
som har vart minst 3 måneder sammenhengende?  
____ JA  
____ NEI 
 
44. Har du i løpet av det siste året hatt smerter eller stivhet i muskulaturen (utenom nakke/skuldre) 
som har vart minst 3 måneder sammenhengende?  
____ JA  
____ NEI 
 
45. Hvis ja, angi hvilken muskulatur _________________________________________________ 
 
46. Alder da hodepinen begynte og varighet av hodepinen (år): 
 ____ alder 
 ____ varighet 
 
47. Klassifikasjon av hodepine (IHS-kriteriene). Sett 1 foran den mest fremtredende hodepinen, 
deretter 2,3 osv for de øvrige hodepinene avhengig av hvor fremtredende de er 
____ Migrene uten aura      
____ Migrene med aura 
____ Familiær hemiplegisk migrene    
____ Basilarismigrene 
____ Kronisk migrene  
____ Episodisk tensjonshodepine  
____ Kronisk tensjonshodepine     
____ Episodisk hortons hodepine (klasehodepine)  
____ Kronisk hortons hodepine (klase)   
____ Episodisk CPH       
____ Kronisk CPH  
____ Kronisk daglig hodepine     
____ Medikament overforbrukshodepine (mistanke) 
____ Annen primær hodepine (jfr. IHS-kriteriene), beskriv: _______________________ 
____ Annen trigeminoautonom hodepine, beskriv _______________________________ 
____ Ikke-klassifiserbar hodepine (verken primær eller sekundær hodepine) 
 
 





50. Har du søvnproblemer?  
____ Nei  
____ Ja 
 
51a Når du har søvnproblemer, har du minst 3 ganger per uke, og i mer enn 1 måned hatt problemer 
med å sovne inn og/eller vansker med å holde søvnen ved like? 
____ Nei  
____ Ja 
 




51c Hvis anfallsvis hodepine – har du mer anfall om dagen?  
____ Nei 
____ Ja 
51c Hvis anfallsvis hodepine – har du mer anfall i helgene?  
____ Nei uendret 
____ Nei mindre 
____ Ja mer 
51d Hvis anfallsvis hodepine (også kronisk hodepine med anfallsvise forverringer)  – har du mer anfall 
i den lyse eller mørke årstiden (om sommeren)?  
____ Nei 
____ Ja, mer anfall i den lyse årstiden 
____ Ja, mer anfall i den mørke årstiden 
____ Ja, mer anfall i overgangen til den lyse årstiden 
____ Ja, mer anfall i overgangen til den mørke årstiden 
____ Nei, ingen månedsvariasjon 
____ Ja, mer anfall følgende måned(er): ________________ 
 
 




51f Brukes ”hjelpemidler” for å redusere lyspåvirkningen (slå av lys, solbriller, persienner etc)? 
____ Nei 
____ Ja, beskriv hvilket tiltak: ______________________ 
 




52. Er det startet behandling mot hodepine ved konsultasjonen? 
____ Nei 
____ Nei, men riktig bruk av medikamenter ble anbefalt pga. feilbruk, 
beskriv_______________________ 
____ Ja, medikamenter (hvilke) _________________________ 
____ Ja, annen behandling (beskriv) _____________________ 
 
52b Er det gitt råd til pasienten om hvordan hodepinen kan takles bedre? 
____ Ja, hvilke råd: __________________________________________ 
____ Nei 
 
53. Har nevrolog rekvirert supplerende undersøkelser? 
____ Nei 
____ Ja, MR/CT (beskriv) _________________________ 
____ Ja, annen utredning (beskriv) ______________________ 
 
54a. Er det gjort avtale om oppfølging? 
____ Nei 
____ Ja, oppfølging hos fastlegen (hva skal følges opp) _________________________ 
____ Ja, oppfølging hos nevrolog (hva skal følges opp)______________________ 
 
54b Er diagnosen fra nevrolog endret i forhold til henvisningsbrevet 
____ Nei 
____ Ja, diagnosen fra henvisningen var riktig, men nevrolog fant en eller flere tilleggshodepiner 
____ Ja, diagnosen fra feil, dvs. at nevrolog har anført ny diagnose 
 
55. Tidspunkt for avslutning av konsultasjon:  
Time ______  
Min ______ 
 
56. Konsultasjonstid: _________ minutter 
 
57. Problemer med videoutstyret:  
____ Ja, beskriv _________________________________________  
____ Nei   
____ Fornøyd med videooverføring 
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Spørreskjemaet fylles ut og returneres  




59. Dato for utfylling: __________________   
 
60. Var du fornøyd med konsultasjonen hos nevrolog?  
____ Ja   




____ Jeg var misfornøyd med å treffe spesialist gjennom videooverføring 
____ Jeg var fornøyd med å treffe spesialist gjennom videooverføring 
 
61. Har hodepinen forandret seg siden konsultasjonen? Sett ett eller flere kryss 
____ Ja, bedre 
____ Antall hodepinedager har avtatt 
____ Hodepinen har blitt mindre intens 
____ Annet 
 
____ Nei, uforandret 
____ Nei, verre 
____ Antall hodepinedager har økt 
____ Hodepinen har blitt mer intens 
____ Misfornøyd med å treffe spesialist gjennom videooverføring 
____ Annet 
 
62. Hvor mange hodepinedager har du hatt i gjennomsnitt de siste 3 måneder? 
____ over 15 dager  
____ 7-15 dager  
____ under < 7 dager 
63. Hvis varigheten av hodepinen er under 4 døgn: Hvor mange slike ”anfall” per måned 
har du hatt i gjennomsnitt de siste 3 måneder? 
____ anfall per måned 
 
64. Hvis du har daglig hodepine: Hvor mange ”anfall” per dag (gjennomsnitt siste 3 
måneder)?  
____  hodepineanfall per dag 
 
65. Bruker du medikamenter nå? 
____ Smertestillende  
____ P-piller  
____ Annen medisin, hvilken _____________________ 
____ Ingen medisiner (reseptbelagte og/eller reseptfrie) 
____ Kosttilskudd, hvilke(n) _____________________ 
____ Naturpreparater, hvilke(n) ___________________ 
____ Andre ”alternative preparater”, hvilke(n) _________________________ 
____ Annen alternativ behandling, hvilken(n) __________________________ 
 
66. Hvor ofte bruker du smertestillende medisiner? 
____ Hver dag 
____ Minst 3 dager per uke  
____ 1-2 dager per uke  
____ Mindre enn 1 dag per uke, men minst annenhver uke  
____ Sjeldnere enn hver annen uke 
____ Minst 15 dager per måned 
 




68. Bruker du migrenemedikamenter? 
____ Nei  
____ Imigran/Zomig/Naramig/Maxalt/Relpax/Almogran (sett strek under) 
 
69. Hvor ofte bruker du migrenemedisiner? 
____ Hver dag 
____ Minst 3 dager per uke  
____ 1-2 dager per uke  
____ Mindre enn 1 dag per uke, men minst annenhver uke  
____ Sjeldnere enn hver annen uke  
____ Minst 15 dager per måned 
 
70. Hvis annen medisin, skriv navn på medikamentet 
____________________________________ 
 
71. Hvilken diagnose fikk du hos nevrolog?  
____________________________________ 
____ Husker ikke 
 
72. Dersom du fikk anbefalt medikamentell behandling hos nevrolog; har du brukt disse 
som foreskrevet?  
____ Ja  
____ Nei 
 
Hvis ikke; hvorfor: ____________________________________________________ 
 
73. VAS (smerteskala fra 0-10) 
Vi ber deg angi graden (intensiteten) av hodepine fra svært lite til svært mye. Skalaen går fra 0-10 der 
0 er ingen hodepine, mens 10 er svært intens hodepine. 
 
Min nåværende hodepine: ________ (angi et tall fra 0-10) 
74. HIT-6  
Spørre skjema om innvirkningen av hodepine på livet ditt. Dette spørreskjemaet er blitt utformet for 
å hjelpe deg med å beskrive og gi uttrykk for hvordan du har det, og hva du ikke kan gjøre pga. 
hodepine.  
 
Vennligst kryss av i passende rute for hvert spørsmål: 
1. Når du har hodepine, hvor ofte er smertene sterke? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
2. Hvor ofte begrenser hodepinen deg til å utføre vanlige daglige gjøremål slik som husarbeid, arbeid, 
skolearbeid eller å ha sosial omgang? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
3. Når du har hodepine, hvor ofte ønsker du at du kunne legge deg ned? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
4. I de siste 4 ukene, hvor ofte har du følt deg for trett til å utføre arbeid eller daglige gjøremål på 
grunn av hodepine? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
5. I de siste 4 ukene, hvor ofte har du følt deg lut lei eller irritert på grunn av hodepine? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
6. I de siste 4 ukene, hvor ofte har hodepinen begrenset din evne til å konsentrere deg om arbeid 
eller daglige gjøremål? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
75. Hva er din hovedaktivitet? (sett ett kryss) 
____ Yrkesaktiv heltid    
____ Militærtjeneste 
____ Yrkesaktiv deltid    
____ Arbeidsledig 
____ Hjemmeværende 
____ Pensjonist/trygdet    
____ Student 
____ Annet, beskriv _________________________     
 
76. Mottar du noen av følgende ytelser? 
____ Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon 
____ Sykepenger (er sykmeldt) 
____ Rehabiliterings-/attføringspenger 
____ Uføreytelse/pensjon, hel 
____ Uføreytelse/pensjon, delvis 
____ Dagpenger eller arbeidsledighet 
____ Overgangsstønad 
____ Sosialhjelp/-stønad 
____ Annet, beskriv _________________________ 
 
77. Hvis du er arbeidsufør pga. hodepine; hvor lenge har arbeidsuførheten vart: 







78. Har det vært endring i din trygdestatus i oppfølgingstiden? 
____ Nei 
____ Ja, friskmeldt pga. hodepine 
____ Ja, friskmeldt pga. sykdom 
____ Ja, sykmeldt pga. hodepine (tidligere vært arbeidsfør) 
____ Annet, beskriv 
 
 
79. Antall konsultasjoner pga. hodepine hos fastlegen i oppfølgingstiden:  
____ konsultasjoner 
 
80. Årsak(er) til konsultasjon hos fastlegen i oppfølgingstiden 
1. konsultasjon 
____ Hodepine 
____ Annet, beskriv: _______________________________ 
2. konsultasjon 
____ Hodepine 
____ Annet, beskriv: _______________________________ 
3. konsultasjon 
____ Hodepine 
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Spørreskjemaet fylles ut og returneres  









6. Tolv-måneders oppfølging (spørreskjema) 
 
Dato for utfylling: __________________ 
 




Angi på en skala fra 0 til 10 der 0 er minst fornøyd og 10 er mest fornøyd:         
 
____ Jeg var misfornøyd med å treffe spesialist gjennom videooverføring 
____ Jeg var misfornøyd med å treffe spesialisten direkte gjennom konsultasjon 
 

































Var du fornøyd med de rådene du fikk av fastlegen for å bedre hodepinen? 
____ Ja 
____ Nei 




Var du fornøyd med kommunikasjonen med fastlegen? 
____ Ja 
____ Nei 
83. Har hodepinen forandret seg siden konsultasjonen?  Sett ett eller flere kryss 
____ Ja, bedre 
____ Antall hodepinedager har avtatt 
____ Hodepinen har blitt mindre intens 
____ Annet______________ 
 
____ Nei, uforandret 
____ Nei, verre 
____ Antall hodepinedager har økt 
____ Hodepinen har blitt mer intens 
____ Annet________________ 
 
84. Hvor mange hodepinedager har du hatt i gjennomsnitt de siste 3 måneder:   
____ over 15 dager  
____ 7-15 dager  
____ under < 7 dager 
 
85. Hvis varigheten av hodepinen er under 4 døgn: Hvor mange slike ”anfall” per måned 
har du hatt i gjennomsnitt de siste 3 måneder? 
____ anfall per måned 
 
86. Hvis du har daglig hodepine: Hvor mange ”anfall” per dag (gjennomsnitt siste 3 
måneder): _____ hodepineanfall per dag 
 
87.   Bruker du medikamenter eller andre preparater? 
____ Smertestillende_____________  
____ P-piller  
____ Annen medisin, hvilken _____________________ 
____ Ingen medisiner (verken reseptbelagte eller reseptfrie) 
____ Kosttilskudd, hvilke(n) _____________________ 
____ Naturpreparater, hvilke(n) ___________________ 
____ Andre ”alternative preparater”, hvilke(n) _________________________ 
____ Annen alternativ behandling, hvilken(n) __________________________ 
 
88. Hvor ofte bruker du smertestillende medisiner? 
____ Hver dag 
____ Minst 3 dager per uke  
____ 1-2 dager per uke  
____ Mindre enn 1 dag per uke, men minst annenhver uke  
____ Sjeldnere enn hver annen uke 
____ Minst 14 dager per måned 
 




90. Bruker du migrenemedikamenter? 
____ Nei  
____ Imigran/Zomig/Naramig/Maxalt/Relpax/Almogran (sett strek under) 
 
91. Hvor ofte bruker du migrenemedisiner? 
____ Hver dag 
____ Minst 3 dager per uke  
____ 1-2 dager per uke  
____ Mindre enn 1 dag per uke, men minst annenhver uke  
____ Sjeldnere enn hver annen uke  
____ Minst 14 dager per måned 
 




93. Hvilken diagnose fikk du hos nevrolog? ____________________________________ 
____ Husker ikke 
 
94. Dersom du fikk anbefalt medikamentell behandling hos nevrolog, hvilken?______; ar 
du brukt den/disse som foreskrevet? 
____ Ja   
____ Nei 
 
Hvis ikke; hvorfor: ____________________________________________________ 
 
95. VAS (smerteskala fra 0-10) 
Vi ber deg angi graden (intensiteten) av hodepine fra svært lite til svært mye. Skalaen går fra 
1-10 der 1 er lite intens hodepine, mens 10 er svært intens hodepine. 
 
Min nåværende hodepine: ________ (angi et tall fra 0-10) 
 
96. Har du tatt bildediagnostikk av hodet? 
   
____ Ja MR 
____ Ja CT 










97. HIT-6  
Vennligst kryss av i passende rute for hvert spørsmål: 
1. Når du har hodepine, hvor ofte er smertene sterke? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
2. Hvor ofte begrenser hodepinen deg til å utføre vanlige daglige gjøremål slik som husarbeid, arbeid, 
skolearbeid eller å ha sosial omgang? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
3. Når du har hodepine, hvor ofte ønsker du at du kunne legge deg ned? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
4. I de siste 4 ukene, hvor ofte har du følt deg for trett til å utføre arbeid eller daglige gjøremål på 
grunn av hodepine? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
5. I de siste 4 ukene, hvor ofte har du følt deg lut lei eller irritert på grunn av hodepine? 
 
⁭ Aldri ⁭ Sjelden ⁭ Noen ganger ⁭ Svært ofte ⁭ Alltid 
 
6. I de siste 4 ukene, hvor ofte har hodepinen begrenset din evne til å konsentrere deg om arbeid 
eller daglige gjøremål? 
 




98. Hva er din hovedaktivitet nå? (sett ett kryss) 
____ Yrkesaktiv heltid    
____ Militærtjeneste 
____ Yrkesaktiv deltid    
____ Arbeidsledig 
____ Hjemmeværende 
____ Pensjonist/trygdet    
____ Student 
____ Annet, beskriv _________________________     
 
99. Mottar du noen av følgende ytelser? 
____ Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon 
____ Sykepenger (er sykmeldt) 
____ Rehabiliterings-/attføringspenger 
____ Uføreytelse/pensjon, hel 
____ Uføreytelse/pensjon, delvis 




____ Annet, beskriv _________________________ 
 
100. Hvis du er arbeidsufør pga. hodepine; hvor lenge har arbeidsuførheten vart: 






101. Har det vært endring i din trygdestatus i oppfølgingstiden? 
____ Nei 
____ Ja, friskmeldt pga. hodepine 
____ Ja, friskmeldt pga. sykdom 
____ Ja, sykmeldt pga. hodepine (tidligere vært arbeidsfør) 
____ Annet, beskriv 
 
102.Hvor ofte driver du mosjon? (med mosjon mener vi at du for eksempel går en tur, går 
på ski, svømmer eller driver trening/idrett) 
____ Aldri 
____ Sjeldnere enn en gang i uken 
____ En gang i uken 
____ 2-3 ganger per uke 
____ Omtrent hver dag 
 
103. Hvor hardt mosjonerer du da i gjennomsnitt? 
____ Tar det rolig uten å bli andpusten eller svett 
____ Tar det så hardt at jeg blir andpusten og svett 
____ Tar meg neste helt ut 
____ Mosjonerer ikke 
 
104. Hvor lenge holder du på hver gang i gjennomsnitt? 
____ Mindre enn 15 minutter 
____ 15-29 minutter 
____ 30 minutter – 1 time 
____ Mer enn 1 time 
 
105. Antall konsultasjoner pga. hodepine hos fastlegen etter konsultasjonen hos nevrolog 
for ett år siden: 
____ konsultasjoner 
 
106. Antall konsultasjoner pga. hodepine hos nevrolog etter konsultasjonen hos nevrolog 
for ett år siden: 
____ konsultasjoner 
 




108. Sett i lys av min tidligere erfaring, vil jeg ved hodepine-konsultasjon hos spesialist 
foretrekke: 
___Ordinær konsultasjon  




















The cheapest means of public transport per headache patient from different municipalities to 
and from Tromsø University Hospital. Calculated with the Norwegian Patient Travel Agency 
probabilistic method.  
Municipality/Location       €    NKR                                                                                  
       
Hammerfest 443 4000 
Alta 443 4000 
Kirkenes 443 4000 
Varangerbotn 443 4000 
Vardø 443 4000 
Vadsø 443 4000 
Bodø 443 4000 
Vestre Jakobselv 443 4000 
Sandnessjøen 443 4000 
Gamvik 443 4000 
Lakselv 443 4000 
Hesseng 443 4000 
Tana 443 4000 
Kvalsund 443 4000 
Øksfjord 443 4000 
Hasvik 443 4000 
Børselv 443 4000 
Kjøllefjord 443 4000 
Skarsvåg 443 4000 
Bjørnevatn 443 4000 
Nordvågen 443 4000 
Båtsfjord 443 4000 
Longyearbyen 443 4000 
Dyfjord 443 4000 
Karasjok 443 4000 
Bjerka 443 4000 
Honningsvåg 443 4000 
Svanvik 443 4000 
Rypefjord 443 4000 
Melbu 443 4000 
Kautokeino 443 4000 
Havøysund 443 4000 
Langfjordbotn 443 4000 
Stokmarknes 443 4000 
Sørvær 443 4000 
Bogen i Lofoten 249 2250 
Tovik 249 2250 
Gratangen 249 2250 
Ballangen 249 2250 
Hamnvik 249 2250 
Senjahopen 249 2250 
Beisfjord 249 2250 
Tennevold 249 2250 
Grillefjord 249 2250 
Hamnvik 249 2250 
Bardu 249 2250 
Gibostad 249 2250 
Liland 249 2250 
Fjordgård 249 2250 
Flakstadvåg 249 2250 
Kjøpsvik 249 2250 
Grovfjord 249 2250 
Stongelandeidet 249 2250 
Kongsvik 249 2250 
Harstad 83 750 
Narvik 83 750 
Finnsnes 83 750 
Silsand 83 750 
Sørstraumen 83 750 
Sørkjosen 83 750 
Sørreisa 83 750 
Sørvik 83 750 
Storslett 83 750 
Rotsund 83 750 
Vangsvik 83 750 
Ankenesstrand 83 750 
Evenskjær 83 750 
Vannvåg 83 750 
Burfjord 83 750 
Bardu 83 750 
Stakkvik 83 750 
Bjerkvik 83 750 
Rossfjordstraumen 83 750 
Moen 83 750 
Ankenes 83 750 
Bardufoss 83 750 
Bardufoss 33 300 
Furuflaten 33 300 
Hamneide 33 300 
Hansnes 33 300 
Karlstad 33 300 
Kvaløya 33 300 
Kvaløysletta 33 300 
Laksvatn 33 300 
Lyngseidet 33 300 
Meistervik 33 300 
Moen 33 300 
Oteren 33 300 
Ramfordbotn 33 300 
Sjøvegan 33 300 
Skjervøy 33 300 
Sommarøya 33 300 
Storsteinnes 33 300 
Straumsbukta 33 300 
Tromsø 6 50 
Tromsdalen 6 50 
Kvaløysletta 6 50 
Tomasjord 6 50 
Krokelvdalen 6 50 
Kvaløya 6 50 
Eidkjosen 6 50 
       
Colour code:  
Blue: Patients travelling by airplane (NKR 4000) 
Red: Patients travelling by taxi and buss or boat (NKR 2250) 
Orange: Patients living along the E6 road or can take the boat (NKR 750) 
Yellow: Patients living outside Tromsø travelling by the district buss (NKR 300) 
Green: Patients living in Tromsø City (NKR 50) 
 
Study patients (N) location and travel cost in Euros (€) and Norwegian Kroner (NKR). 
Calculations of travel costs are based on the previous table.  
  Patient location        N   €         NKR                                             
           
 Alta 33 14619 132000 
Ankenes 1 83 750 
Ankenesstrand 5 415 3750 
Ballangen 3 747 6750 
Bardu 6 664 6000 
Bardufoss 4 182 1650 
Beisfjord 2 498 4500 
Bjerka 1 443 4000 
Bjerkvik 3 249 2250 
Bjørnevatn 1 443 4000 
Bodø 1 443 4000 
Bogen i Lofoten 1 249 2250 
Burfjord 1 83 750 
Børselv 1 443 4000 
Båtsfjord 2 886 8000 
Dyfjord 1 443 4000 
Eidkjosen 1 6 50 
Evenskjær 4 332 3000 
Finnsnes 9 747 6750 
Fjordgård 1 249 2250 
Flakstadvåg 1 249 2250 
Furuflaten 1 33 300 
Gamvik 1 443 4000 
Gibostad 1 249 2250 
Gratangen 1 249 2250 
Grovfjord 1 249 2250 
Gryllefjord 1 249 2250 
Hammerfest 18 7974 72000 
Hamneide 1 33 300 
Hamnvik 3 747 6750 
Hansnes 4 132 1200 
Harstad 10 830 7500 
Hasvik 4 1772 16000 
Havøysund 1 443 4000 
Hesseng 2 886 8000 
Honningsvåg 2 886 8000 
Karasjok 3 1329 12000 
Karlstad 3 99 900 
Kautokeino 3 1329 12000 
Kiberg 1 443 4000 
Kirkenes 3 1329 12000 
Kjøllefjord 1 443 4000 
Kjøpsvik 1 249 2250 
Kongsvik 1 249 2250 
Krokelvdalen 6 33 300 
Kvalsund 3 1329 12000 
Kvaløya 6 63 550 
Kvaløysletta 19 249 2200 
Lakselv 4 1772 16000 
Laksvatn 1 33 300 
Langfjordbotn 1 443 4000 
Liland 2 498 4500 
Longyearbyen 2 886 8000 
Lyngseidet 2 66 600 
Meistervik 4 132 1200 
Melbu 1 443 4000 
Moen 5 215 1950 
Narvik 16 1329 12000 
Nordvågen 1 443 4000 
Oteren 1 33 300 
Ramfjordbotn 2 66 600 
Rossfjordstraumen 2 166 1500 
Rotsund 1 83 750 
Russenes 1 443 4000 
Rypefjord 1 443 4000 
Sandnessjøen 1 443 4000 
Senjahopen 3 747 6750 
Silsand 4 332 3000 
Sjøvegan 3 99 900 
Skarsvåg 1 443 4000 
Skjervøy 6 198 1800 
Sommarøya 1 33 300 
Stakkvik 2 166 1500 
Stokmarknes 1 443 4000 
Stongelandeidet 1 249 2250 
Storslett 7 581 5250 
Storsteinnes 4 132 1200 
Straumsbukta 1 33 300 
Svanvik 1 443 4000 
Sørkjosen 3 249 2250 
Sørreisa 14 1162 10500 
Sørstraumen 1 83 750 
Sørvik 1 83 750 
Sørvær 2 886 8000 
Talvik 1 443 4000 
Tana 6 2658 24000 
Tennevold 2 498 4500 
Tomasjord 8 48 400 
Tovik 2 498 4500 
Tromsdalen 14 84 700 
Tromsø 62 372 3100 
Vadsø 6 2658 24000 
Vangsvik 1 83 750 
Vannvåg 1 83 750 
Varangerbotn 4 1772 16000 
Vardø 3 1329 12000 
Veste Jakobselv 1 443 4000 
Øksfjord 4 1772 16000 
                                                                        
Grand Total          402    71832          648350                                                                           
          
 
 
 
 
 
 
 
 
 
 
 
